PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 2568020-1 1989 Both quinoline and 8-hydroxyquinoline (HOQ) were tested for their genotoxicity in CD1 male mice by using a bone marrow micronucleus assay. quinoline 5-14 CD1 antigen complex Mus musculus 82-85 2502633-5 1989 All of the 6-quinolylmethyl derivatives were highly inhibitory against Escherichia coli dihydrofolate reductase (DHFR), provided that an 8-substituent was present in the quinoline ring. quinoline 170-179 Dihydrofolate reductase Escherichia coli 88-111 2502633-5 1989 All of the 6-quinolylmethyl derivatives were highly inhibitory against Escherichia coli dihydrofolate reductase (DHFR), provided that an 8-substituent was present in the quinoline ring. quinoline 170-179 Dihydrofolate reductase Escherichia coli 113-117 2502633-6 1989 Those compounds that had basic substituents in the 2-position of the quinoline ring were also highly specific for bacterial dihydrofolate DHFR, relative to a vertebrate counterpart. quinoline 69-78 Dihydrofolate reductase Escherichia coli 138-142 3346669-7 1988 The relationship of the chemical structure of structurally related quinoline and isoquinoline derivatives to inhibition of the activity of type A or B MAO was examined. quinoline 67-76 monoamine oxidase A Homo sapiens 151-154 3116135-2 1987 All raised the intracellular concentration of free calcium (Ca2+ i) of cells loaded with a fluorescent quinoline Ca2+ indicator in suspension, but the effect of TRH was much more rapid and less prolonged than that of VIP and EGF. quinoline 103-112 thyrotropin releasing hormone Rattus norvegicus 161-164 6770893-7 1980 Derivatives with quinoline nuclei are notable for their high sensitivity of fluorescent quantum yield to the binding of Ca2+ but not of Mg2+. quinoline 17-26 carbonic anhydrase 2 Homo sapiens 120-123 3104257-0 1987 The carcinogenicity of quinoline and benzoquinolines in newborn CD-1 mice. quinoline 23-32 CD1 antigen complex Mus musculus 64-68 6744247-3 1984 Additional evidence is provided by the regiochemistry of cytochrome P-450 catalyzed oxidation of quinoline. quinoline 97-106 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 57-73 3821373-0 1987 Quinoline and quninaldine as naturally occurring inhibitors specific for type A monoamine oxidase. quinoline 0-9 monoamine oxidase A Homo sapiens 80-97 3821373-1 1987 Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate. quinoline 128-137 monoamine oxidase A Homo sapiens 7-24 3821373-1 1987 Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate. quinoline 128-137 monoamine oxidase A Homo sapiens 26-31 3821373-2 1987 Quinoline had a higher affinity for MAO than kynuramine. quinoline 0-9 monoamine oxidase B Homo sapiens 36-39 3821373-3 1987 MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline. quinoline 83-92 monoamine oxidase A Homo sapiens 0-5 3821373-3 1987 MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline. quinoline 83-92 monoamine oxidase B Homo sapiens 0-3 3821373-3 1987 MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline. quinoline 169-178 monoamine oxidase A Homo sapiens 0-5 3821373-3 1987 MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline. quinoline 169-178 monoamine oxidase B Homo sapiens 0-3 3821373-3 1987 MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline. quinoline 169-178 monoamine oxidase B Homo sapiens 112-117 3821373-4 1987 Quinoline inhibited MAO-A much more potently than MAO-B. quinoline 0-9 monoamine oxidase A Homo sapiens 20-25 3821373-5 1987 Of several compounds structurally similar to quinoline, isoquinoline noncompetitively inhibited MAO-A and -B activity. quinoline 45-54 monoamine oxidase A Homo sapiens 96-108 1244091-2 1975 MAO reaction inhibited by quinoline compound and the inhibition of kynurenine aminotransferase activity through the injection of epinephrine or serotonin were observed. quinoline 26-35 monoamine oxidase A Rattus norvegicus 0-3 13501346-0 1957 Inhibition of P 32 incorporation in vitro into nucleic acids of Ehrlich carcinoma cells by quinoline derivatives. quinoline 91-100 complement component 1, q subcomponent binding protein Mus musculus 14-18 4750108-0 1973 Inhibitory effect of some quinoline, phthalazine, and coumarin derivatives on glucose-6-phosphate dehydrogenase in vitro. quinoline 26-35 glucose-6-phosphate dehydrogenase Homo sapiens 78-111 4149496-0 1974 Effect of quinoline, phthalazine and coumarin derivatives on the absorbance of NADPH. quinoline 10-19 2,4-dienoyl-CoA reductase 1 Homo sapiens 79-84 33783213-0 2021 Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion. quinoline 67-76 folate hydrolase 1 Homo sapiens 88-92 33892270-0 2021 Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition. quinoline 21-30 cytochrome c oxidase II, mitochondrial Mus musculus 145-150 33892270-0 2021 Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition. quinoline 21-30 arachidonate 15-lipoxygenase Mus musculus 155-161 33892270-1 2021 Based on the observed pharmacophoric structural features for the reported dual COX/15-LOX inhibitors and inspired by the abundance of COX/LOX inhibitory activities reported for the 1,2,4-triazine and quinoline scaffolds, we designed and synthesized novel 1,2,4-triazine-quinoline hybrids (8a-n). quinoline 200-209 cytochrome c oxidase assembly protein 15 Mus musculus 79-85 33892270-1 2021 Based on the observed pharmacophoric structural features for the reported dual COX/15-LOX inhibitors and inspired by the abundance of COX/LOX inhibitory activities reported for the 1,2,4-triazine and quinoline scaffolds, we designed and synthesized novel 1,2,4-triazine-quinoline hybrids (8a-n). quinoline 200-209 lysyl oxidase Mus musculus 138-141 33892270-1 2021 Based on the observed pharmacophoric structural features for the reported dual COX/15-LOX inhibitors and inspired by the abundance of COX/LOX inhibitory activities reported for the 1,2,4-triazine and quinoline scaffolds, we designed and synthesized novel 1,2,4-triazine-quinoline hybrids (8a-n). quinoline 270-279 lysyl oxidase Mus musculus 138-141 33892270-3 2021 The new triazine-quinoline hybrids (8a-n) exhibited potent COX-2 inhibitory profiles (IC50 = 0.047-0.32 muM, SI ~ 20.6-265.9) compared to celecoxib (IC50 = 0.045 muM, SI ~ 326). quinoline 17-26 cytochrome c oxidase II, mitochondrial Mus musculus 59-64 33892270-10 2021 To our knowledge, herein we reported the first 1,2,4-triazine-quinoline hybrids as dual COX/15-LOX inhibitors. quinoline 62-71 cytochrome c oxidase assembly protein 15 Mus musculus 88-94 33892270-10 2021 To our knowledge, herein we reported the first 1,2,4-triazine-quinoline hybrids as dual COX/15-LOX inhibitors. quinoline 62-71 lysyl oxidase Mus musculus 95-98 34058295-9 2021 FQs, which are quinoline derivatives, could also bind to hERG molecules. quinoline 15-24 ETS transcription factor ERG Homo sapiens 57-61 34058295-11 2021 It was found that drugs with a quinoline structure, particularly with high molecular polarity, can exert a significant potential hERG inhibitory activity. quinoline 31-40 ETS transcription factor ERG Homo sapiens 129-133 34038639-0 2021 Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp. quinoline 0-9 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 80-84 34038639-4 2021 In this study, 101 quinoline and quinazoline derivatives were screened against SARS-CoV-2 RdRp using a cell-based assay. quinoline 19-28 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 90-94 33978746-0 2021 Structural recognition of the MYC promoter G-quadruplex by a quinoline derivative: insights into molecular targeting of parallel G-quadruplexes. quinoline 61-70 MYC proto-oncogene, bHLH transcription factor Homo sapiens 30-33 33860988-5 2021 A novel triantennary galactose conjugated quinoline derivative 4 has been synthesized that demonstrates a 17 fold higher binding affinity to isolated ASGPR-H1-CRD protein receptor (K d ~ 54 microM) in comparison to D-Galactose (Kd ~ 900 microM). quinoline 42-51 asialoglycoprotein receptor 1 Homo sapiens 150-155 33783213-2 2021 In this study, three 18F-labeled PSMA tracers with a more lipophilic quinoline functional spacer were designed, synthesized, and evaluated based on the Glu-Ureido-Lys binding motif. quinoline 69-78 folate hydrolase 1 Homo sapiens 33-37 33572333-0 2021 Tuned Cd2+ Selectivity: Showcase of Electronic and Regio-Effect of pi-Extended Di-2-Picolylamine-Substituted Quinoline-Based Tolans. quinoline 109-118 CD2 molecule Homo sapiens 6-9 33348096-0 2021 A quinoline-based fluorescent chemosensor for palladium ion (Pd2+)-selective detection in aqueous solution. quinoline 2-11 PAF1 homolog, Paf1/RNA polymerase II complex component Homo sapiens 61-64 33348096-2 2021 In this work, a novel quinoline-benzimidazole conjugate containing one carboxylic acid group (QBM) was designed, and the QBM displayed highly selective fluorescence quenching response towards Pd2+ over other metal cations in aqueous solution. quinoline 22-31 PAF1 homolog, Paf1/RNA polymerase II complex component Homo sapiens 192-195 33662256-3 2021 The quinoline of CAM833 occupies a hotspot, the Phe-binding pocket on RAD51 and the methyl of the substituted alpha-methylbenzyl group occupies the Ala-binding pocket. quinoline 4-13 RAD51 recombinase Homo sapiens 70-75 33560123-0 2021 Cu(OTf)2-Catalyzed Intramolecular Radical Cascade Reactions for the Diversity-Oriented Synthesis of Quinoline-Annulated Polyheterocyclic Frameworks. quinoline 100-109 POU class 2 homeobox 2 Homo sapiens 0-8 33560123-2 2021 Herein, we report the first Cu(OTf)2-catalyzed intramolecular radical cascade reactions that enable the diversity-oriented synthesis of quinoline-annulated polyheterocyclic compounds (7 unique scaffolds, 66 examples) in an efficient manner. quinoline 136-145 POU class 2 homeobox 2 Homo sapiens 31-36 33661013-2 2021 Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC50 < 200 nM). quinoline 45-54 DNA methyltransferase 1 Homo sapiens 153-176 33475631-3 2021 In this work, a steric hindrance effect was observed in a quinoline-involved polypyridyl Co complex-based water reduction catalyst (WRC), which impedes the formation of Co(iii)-H from Co(i), two pivotal intermediates for H2 evolution, leading to significantly impaired electrocatalytic and photocatalytic activity with respect to its parent complex, [Co(TPA)Cl]Cl (TPA = tris(2-pyridinylmethyl)-amine). quinoline 58-67 mitochondrially encoded cytochrome c oxidase I Homo sapiens 184-189 33644006-1 2020 Molecular docking studies of quinoline and 2-chloroquinoline substrates at the active site of toluene dioxygenase (TDO), were conducted using Autodock Vina, to identify novel edge-to-face interactions and to rationalize the observed stereoselective cis-dihydroxylation of carbocyclic rings and formation of isolable cis-dihydrodiol metabolites. quinoline 29-38 tryptophan 2,3-dioxygenase Homo sapiens 115-118 33644006-2 2020 These in silico docking results of quinoline and pyridine substrates, with TDO, also provided support for the postulated cis-dihydroxylation of electron-deficient pyridyl rings, to give transient cis-dihydrodiol intermediates and the derived hydroxyquinolines. quinoline 35-44 tryptophan 2,3-dioxygenase Homo sapiens 75-78 33563156-7 2022 Two compounds, quinoline-1 and coumarin-24, were found to be effective on three targets - S2, TMPRSS2 and furin - simultaneously, with good predicted affinity between -7.54 to -8.85 kcal/mol. quinoline 15-24 transmembrane serine protease 2 Homo sapiens 94-101 33563156-7 2022 Two compounds, quinoline-1 and coumarin-24, were found to be effective on three targets - S2, TMPRSS2 and furin - simultaneously, with good predicted affinity between -7.54 to -8.85 kcal/mol. quinoline 15-24 furin, paired basic amino acid cleaving enzyme Homo sapiens 106-111 33137400-4 2021 Interestingly, preclinical studies in rodents suggest that chronic pharmacological activation of SERCA2 by the quinoline derivative CDN1163 comprises a potential pharmacotherapeutic target in Alzheimer"s and Parkinson"s diseases. quinoline 111-120 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 Mus musculus 97-103 33494672-6 2021 Results and Conclusion: It was observed that structures of the GSK-3 inhibitors comprised of benzopyridine, benzthiazole, pyrazole, pyrazine, dioxolo-benzoxazin, oxadiazole, benzimidazole in the skeletal with cyclopropylamide, phenyl carbamothioate, 3-[(propan-2-yl)oxy]propan-1-amine in side chain. quinoline 93-106 glycogen synthase kinase 3 beta Mus musculus 63-68 33476869-0 2021 Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). quinoline 79-88 epidermal growth factor receptor Homo sapiens 151-155 33476869-13 2021 The built model will assist to design, refine and construct novel substituted quinoline derivatives as potent EGFR inhibitors in near future. quinoline 78-87 epidermal growth factor receptor Homo sapiens 110-114 33279248-0 2021 Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. quinoline 30-39 epidermal growth factor receptor Homo sapiens 116-120 32993862-5 2020 Herein, two quinoline-based AIE probes were designed and synthesized for the imaging of Abeta plaques and lipid droplets. quinoline 12-21 histocompatibility 2, class II antigen A, beta 1 Mus musculus 88-93 33199201-0 2021 The discovery of quinoline derivatives, as NF-kappaB inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth. quinoline 17-26 mitogen-activated protein kinase kinase kinase 14 Homo sapiens 43-68 33199201-0 2021 The discovery of quinoline derivatives, as NF-kappaB inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth. quinoline 17-26 mitogen-activated protein kinase kinase kinase 14 Homo sapiens 70-73 33289376-0 2021 Quinoline-Fused Lactones via Tandem Oxidation Cyclization: Metal-Free sp3 C-H Functionalization. quinoline 0-9 Sp3 transcription factor Homo sapiens 70-73 33339080-0 2020 Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). quinoline 70-79 epidermal growth factor receptor Homo sapiens 146-150 33339080-0 2020 Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). quinoline 70-79 epidermal growth factor receptor Homo sapiens 162-166 32971427-4 2020 TAMs bearing benzotrifluoride, naphthol or heteroaromatic (indole, quinoline or thiophene) rings seem to be prone to AhR activation unlike phenyl substituted or benzotriazole derivatives. quinoline 67-76 aryl hydrocarbon receptor Homo sapiens 117-120 32592325-8 2020 OTU1 replaced OTU8 (Thauera) as the most predominant denitrifying quinoline degrading member. quinoline 66-75 OTU deubiquitinase, ubiquitin aldehyde binding 1 Homo sapiens 0-4 32592325-11 2020 Although the abundance of OTU1 was much lower initially, it replaced the essential role of the predominant member OTU8 in the bioreactor community for quinoline degradation once the environmental condition changed. quinoline 151-160 OTU deubiquitinase, ubiquitin aldehyde binding 1 Homo sapiens 26-30 33074120-4 2020 Quinoline derivatives 3f and 3g were identified as potent hDHODH inhibitors while 3k and 3l demonstrated high cytotoxic activity against MCF-7 and A375 cells and good selectivity. quinoline 0-9 dihydroorotate dehydrogenase (quinone) Homo sapiens 58-64 33080494-0 2020 Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. quinoline 69-78 phosphodiesterase 5A Homo sapiens 103-107 33080494-2 2020 Accordingly, we report the synthesis of series of pyrazolo[3,4-d]pyrimidin-4-one carrying quinoline moiety (11a-r) with potential dual PDE5 inhibition and apoptotic induction for cancer treatment. quinoline 90-99 phosphodiesterase 5A Homo sapiens 135-139 33252031-0 2022 Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study. quinoline 36-45 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 77-82 33252031-3 2022 A set of 58 molecules belongs to the naphthyridine and quinoline derivatives have been recently synthesized and considered for structure-based virtual screening against Nsp16-Nsp10. quinoline 55-64 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 175-180 32527559-0 2020 Discovery of quinoline-based irreversible BTK inhibitors. quinoline 13-22 Bruton tyrosine kinase Homo sapiens 42-45 32990536-6 2021 In this review, we summarize the recent literature on small molecule and peptide inhibitors of Mcl-1, which are divided into different types including: peptide inhibitors, gossypol derivatives, marinopyrrole derivatives, S1 derivatives, indole derivatives, quinoline derivatives, S63845, AZD5991, AMG176, etc. quinoline 257-266 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 95-100 32537757-6 2020 All tested quinoline derivatives were found to be effective inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase I and II isoforms (hCA I and II), with Ki values of 46.04-956.82 nM for hCA I, 54.95-976.93 nM for hCA II, and 5.51-155.22 nM for AChE. quinoline 11-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-94 32537757-6 2020 All tested quinoline derivatives were found to be effective inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase I and II isoforms (hCA I and II), with Ki values of 46.04-956.82 nM for hCA I, 54.95-976.93 nM for hCA II, and 5.51-155.22 nM for AChE. quinoline 11-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 96-100 32537757-6 2020 All tested quinoline derivatives were found to be effective inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase I and II isoforms (hCA I and II), with Ki values of 46.04-956.82 nM for hCA I, 54.95-976.93 nM for hCA II, and 5.51-155.22 nM for AChE. quinoline 11-20 carbonic anhydrase 1 Homo sapiens 116-136 32537757-6 2020 All tested quinoline derivatives were found to be effective inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase I and II isoforms (hCA I and II), with Ki values of 46.04-956.82 nM for hCA I, 54.95-976.93 nM for hCA II, and 5.51-155.22 nM for AChE. quinoline 11-20 carbonic anhydrase 2 Homo sapiens 234-240 32537757-6 2020 All tested quinoline derivatives were found to be effective inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase I and II isoforms (hCA I and II), with Ki values of 46.04-956.82 nM for hCA I, 54.95-976.93 nM for hCA II, and 5.51-155.22 nM for AChE. quinoline 11-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 265-269 32492288-0 2020 Chemoenzymatic synthesis and pharmacological evaluation of enantiomerically pure quinoline-based kappa-opioid receptor (KOR) agonists. quinoline 81-90 opioid receptor kappa 1 Homo sapiens 97-118 32492288-0 2020 Chemoenzymatic synthesis and pharmacological evaluation of enantiomerically pure quinoline-based kappa-opioid receptor (KOR) agonists. quinoline 81-90 opioid receptor kappa 1 Homo sapiens 120-123 32793181-5 2020 Out of 113 quinoline-drugs, elvitegravir and oxolinic acid are able to interact with the NTP entry-channel and thus interfere with the RNA-directed 5"-3" polymerase activity of SARS-CoV-2 RdRp. quinoline 11-20 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 188-192 32793181-8 2020 The result shows rilapladib is the only quinoline that can interrupt the Spike-RBD-ACE2 complex. quinoline 40-49 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 73-78 32793181-8 2020 The result shows rilapladib is the only quinoline that can interrupt the Spike-RBD-ACE2 complex. quinoline 40-49 angiotensin converting enzyme 2 Homo sapiens 83-87 32305837-2 2020 Thus, we designed and synthesized two quinoline-derived Schiff-bases HL1 and HL2, and investigated the fluorescence emission responses of these two Schiff-bases to various metal ions. quinoline 38-47 asialoglycoprotein receptor 1 Homo sapiens 69-72 32305837-2 2020 Thus, we designed and synthesized two quinoline-derived Schiff-bases HL1 and HL2, and investigated the fluorescence emission responses of these two Schiff-bases to various metal ions. quinoline 38-47 intelectin 2 Homo sapiens 77-80 32527559-4 2020 Moving from a quinazoline to a quinoline core provided a handle for selectivity for BTK over EGFR and resulted in the identification of potent and selective BTK inhibitors with good potency in human whole blood assay. quinoline 31-40 Bruton tyrosine kinase Homo sapiens 84-87 32527559-4 2020 Moving from a quinazoline to a quinoline core provided a handle for selectivity for BTK over EGFR and resulted in the identification of potent and selective BTK inhibitors with good potency in human whole blood assay. quinoline 31-40 epidermal growth factor receptor Homo sapiens 93-97 32527559-4 2020 Moving from a quinazoline to a quinoline core provided a handle for selectivity for BTK over EGFR and resulted in the identification of potent and selective BTK inhibitors with good potency in human whole blood assay. quinoline 31-40 Bruton tyrosine kinase Homo sapiens 157-160 32179525-1 2020 The quinoline MK-571 is the most commonly used inhibitor of multidrug resistance protein-1 (MRP-1) but was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. quinoline 4-13 ATP binding cassette subfamily B member 1 Homo sapiens 60-90 32371117-7 2020 Furthermore, N1 nitrogen of the quinoline scaffold formed an essential hydrogen bond with the hinge region key amino acids Ala213 and Ala173 in AURKA and AURKB, respectively. quinoline 32-41 aurora kinase A Homo sapiens 144-149 32371117-7 2020 Furthermore, N1 nitrogen of the quinoline scaffold formed an essential hydrogen bond with the hinge region key amino acids Ala213 and Ala173 in AURKA and AURKB, respectively. quinoline 32-41 aurora kinase B Homo sapiens 154-159 32503697-0 2020 Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. quinoline 76-85 kinase insert domain receptor Homo sapiens 146-153 32502336-4 2020 Starting from quinoline 2 with weak ATR inhibitory activity, lead optimization efforts focusing on potency, selectivity, and oral bioavailability led to the discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344, which exhibited strong monotherapy efficacy in cancer xenograft models that carry certain DNA damage repair deficiencies. quinoline 14-23 ATR serine/threonine kinase Homo sapiens 217-220 32551024-0 2020 Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. quinoline 32-41 receptor interacting serine/threonine kinase 2 Homo sapiens 48-52 32551024-0 2020 Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. quinoline 32-41 ETS transcription factor ERG Homo sapiens 113-117 32179525-1 2020 The quinoline MK-571 is the most commonly used inhibitor of multidrug resistance protein-1 (MRP-1) but was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. quinoline 4-13 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 32179525-1 2020 The quinoline MK-571 is the most commonly used inhibitor of multidrug resistance protein-1 (MRP-1) but was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. quinoline 4-13 cysteinyl leukotriene receptor 1 Homo sapiens 133-165 32179525-1 2020 The quinoline MK-571 is the most commonly used inhibitor of multidrug resistance protein-1 (MRP-1) but was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. quinoline 4-13 cysteinyl leukotriene receptor 1 Homo sapiens 167-174 31521657-0 2020 Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. quinoline 67-76 epidermal growth factor receptor Homo sapiens 121-125 31971798-2 2020 Here we describe the structure-based design and optimization of quinoline lead compounds to identify FT-2102, a potent, orally bioavailable, brain penetrant, and selective mIDH1 inhibitor. quinoline 64-73 isocitrate dehydrogenase 1 (NADP+), soluble Mus musculus 172-177 31756401-0 2020 Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening. quinoline 24-33 euchromatic histone lysine methyltransferase 2 Homo sapiens 48-53 31756401-0 2020 Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening. quinoline 24-33 euchromatic histone lysine methyltransferase 2 Homo sapiens 54-57 31756401-4 2020 Here, we report the discovery of CSV0C018875 as a novel quinoline based G9a inhibitor through virtual screening strategy from a HTS database. quinoline 56-65 euchromatic histone lysine methyltransferase 2 Homo sapiens 72-75 31521657-0 2020 Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. quinoline 67-76 kinase insert domain receptor Homo sapiens 130-137 30850501-5 2019 Methods: Novel quinoline-based radiotracers were synthesized by organic chemistry and evaluated in radioligand binding assays using FAP-expressing HT-1080 cells. quinoline 15-24 fibroblast activation protein alpha Homo sapiens 132-135 31424613-1 2019 Quinoline- and quinazoline-based kinase inhibitors of the epidermal growth factor receptor (EGFR) have been used to target non-small cell lung cancer (NSCLC) and chordomas with varying amounts of success. quinoline 0-9 epidermal growth factor receptor Homo sapiens 58-90 31424613-1 2019 Quinoline- and quinazoline-based kinase inhibitors of the epidermal growth factor receptor (EGFR) have been used to target non-small cell lung cancer (NSCLC) and chordomas with varying amounts of success. quinoline 0-9 epidermal growth factor receptor Homo sapiens 92-96 31349117-0 2019 Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. quinoline 15-24 heat shock protein 90 alpha family class A member 1 Homo sapiens 65-70 31102570-0 2019 Structure-dependent activation of gene expression by bis-indole and quinoline-derived activators of nuclear receptor 4A2. quinoline 68-77 nuclear receptor subfamily 4 group A member 2 Homo sapiens 100-120 31072147-0 2019 Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors. quinoline 54-63 mitogen-activated protein kinase kinase 7 Homo sapiens 155-158 31102570-6 2019 These results demonstrate that although bis-indole and quinoline derivatives have been characterized as activators of NR4A2-dependent gene expression, these two classes of compounds exhibit different activities, indicating that they are selective NR4A2 modulators. quinoline 55-64 nuclear receptor subfamily 4 group A member 2 Homo sapiens 118-123 31102570-6 2019 These results demonstrate that although bis-indole and quinoline derivatives have been characterized as activators of NR4A2-dependent gene expression, these two classes of compounds exhibit different activities, indicating that they are selective NR4A2 modulators. quinoline 55-64 nuclear receptor subfamily 4 group A member 2 Homo sapiens 247-252 30295990-2 2019 Although clinically the diagnosis of AD relies on the use of radiolabeled imaging reagents, herein we report the simple construction of a "flat ensemble" formed between a quinoline-malononitrile AIEgen (EDS) and thin-layer molybdenum disulfide (2D MoS2 ) for the sensitive detection of Abeta by means of fluorescence-based techniques. quinoline 171-180 amyloid beta precursor protein Homo sapiens 286-291 31414521-1 2019 Based on the cabozantinib scaffold, novel c-Met inhibitors were rationalized from the limited knowledge of structure-activity relationships for the quinoline 6-position. quinoline 148-157 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 42-47 31032878-5 2019 EXPERIMENTAL APPROACH: We analysed sensitivity of recombinant Kv 12.1 channels to quinine, a substituted quinoline that blocks Kv 10.1 and Kv 11.1 at low micromolar concentrations. quinoline 105-114 potassium voltage-gated channel subfamily H member 2 Homo sapiens 139-146 31100281-5 2019 Docking studies revealed that the quinoline group within the AChE active site was positioned in the choline binding site, while the C(4)-amino group substituents, depending on their lipophilicity, could establish hydrogen bonds or pi-interactions with residues of the peripheral anionic site. quinoline 34-43 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-65 31158748-4 2019 Analysis of SAR revealed the importance of electron-withdrawing substituents in the styryl part and chelating properties in the quinoline ring. quinoline 128-137 sarcosine dehydrogenase Homo sapiens 12-15 31129051-0 2019 Quinoline and thiazolopyridine allosteric inhibitors of MALT1. quinoline 0-9 MALT1 paracaspase Mus musculus 56-61 31129055-0 2019 Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK). quinoline 78-87 cyclin G associated kinase Homo sapiens 103-129 31129055-0 2019 Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK). quinoline 78-87 cyclin G associated kinase Homo sapiens 131-134 30035675-0 2019 Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors. quinoline 57-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 31031055-0 2019 Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists. quinoline 33-42 purinergic receptor P2X 7 Homo sapiens 60-73 31031055-2 2019 In the present study, the synthesis and structure-activity relationship (SAR) of a novel series of quinoline derivatives as P2X7R antagonists are described herein. quinoline 99-108 purinergic receptor P2X 7 Homo sapiens 124-129 31020956-6 2019 Under optimum conditions (5% Cu doped ZnO, dose of 1.2 g L-1 for pyridine and 1.6 g L-1 for quinoline, pH = 11 and time = 5 h), the maximum pyridine and quinoline mineralization efficiencies were found to be 92.4% and 74.3%, respectively. quinoline 92-101 immunoglobulin kappa variable 1-16 Homo sapiens 84-87 30952319-2 2019 In this work, a quinoline-containing Schiff base, AMQD, was utilized as fluorescence probe for Cd2+. quinoline 16-25 CD2 molecule Homo sapiens 95-98 30753989-1 2019 With the aim to develop a specific radioligand for imaging the cyclic nucleotide phosphodiesterase 5 (PDE5) in brain by positron emission tomography (PET), seven new fluorinated inhibitors (3-9) were synthesized on the basis of a quinoline core. quinoline 230-239 phosphodiesterase 5A, cGMP-specific Mus musculus 102-106 31318346-8 2019 The removal efficiency of quinoline reached more than 97% for a velocity of 6 mL min-1 at the initial adsorption stage. quinoline 26-35 CD59 molecule (CD59 blood group) Homo sapiens 81-86 30940396-4 2019 2-Substituted naphthalene- and quinoline-derived chemotypes emerged as the most interesting prototypes, with C-5 and C-6 substituents enhancing antiviral potency. quinoline 31-40 complement C5 Homo sapiens 109-112 30940396-4 2019 2-Substituted naphthalene- and quinoline-derived chemotypes emerged as the most interesting prototypes, with C-5 and C-6 substituents enhancing antiviral potency. quinoline 31-40 complement C6 Homo sapiens 117-120 31060628-4 2019 RESULTS: Here, we report the identification of a new quinoline-based molecule, MC3353, as a non-nucleoside inhibitor and downregulator of DNMT. quinoline 53-62 DNA methyltransferase 1 Homo sapiens 138-142 30785041-2 2019 In the current piece of work, we have explored the interaction of quinoline yellow (QY) with myoglobin (Mb) at two different pH (3.5 and 7.4). quinoline 66-75 myoglobin Homo sapiens 93-102 30785041-2 2019 In the current piece of work, we have explored the interaction of quinoline yellow (QY) with myoglobin (Mb) at two different pH (3.5 and 7.4). quinoline 66-75 myoglobin Homo sapiens 104-106 30798218-3 2019 In this study, a novel fluorescent probe, QN-1, based on azide group and quinoline derivatives was developed for detecting H2S. quinoline 73-82 centrosomal protein 162 Homo sapiens 42-46 31069214-1 2019 A novel structural series of quinoline derivatives were designed, synthesized and biologically evaluated as PI3K/mTOR dual inhibitors upon incorporation of C-4 acrylamide fragment. quinoline 29-38 mechanistic target of rapamycin kinase Homo sapiens 113-117 30818177-2 2019 It was demonstrated that the replacement of the 3,4,5-trimethoxyphenyl A-ring present in CA-4, isoCA-4 and isoazaerianin by a quinoline or a quinazoline ring is possible and often beneficiary for a high level of cytotoxicity. quinoline 126-135 carbonic anhydrase 4 Homo sapiens 89-93 30897325-0 2019 Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. quinoline 47-56 DNA topoisomerase I Homo sapiens 72-87 30835121-2 2019 This strategy provides the synthesis of valuable SCF3-substituted quinoline and isoquinoline systems via the construction of one C(sp2)-SCF3 bond and one C-N bond within one process. quinoline 66-75 Sp2 transcription factor Homo sapiens 129-134 30835121-2 2019 This strategy provides the synthesis of valuable SCF3-substituted quinoline and isoquinoline systems via the construction of one C(sp2)-SCF3 bond and one C-N bond within one process. quinoline 66-75 KIT ligand Homo sapiens 49-52 30738663-0 2019 Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design. quinoline 44-53 dihydroorotate dehydrogenase (quinone) Homo sapiens 105-111 30599408-0 2019 Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription. quinoline 32-41 heterogeneous nuclear ribonucleoprotein K Homo sapiens 72-79 30738663-1 2019 Following our research for human dihydroorotate dehydrogenase (hDHODH) inhibitors as anticancer agents, herein we describe 3D QSAR-based design, synthesis and in vitro screening of 2-,4,-6-, and/or 7-substituted quinoline derivatives as hDHODH inhibitors and anticancer agents. quinoline 212-221 dihydroorotate dehydrogenase (quinone) Homo sapiens 63-69 30599408-0 2019 Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription. quinoline 32-41 MYC proto-oncogene, bHLH transcription factor Homo sapiens 103-108 30738663-1 2019 Following our research for human dihydroorotate dehydrogenase (hDHODH) inhibitors as anticancer agents, herein we describe 3D QSAR-based design, synthesis and in vitro screening of 2-,4,-6-, and/or 7-substituted quinoline derivatives as hDHODH inhibitors and anticancer agents. quinoline 212-221 dihydroorotate dehydrogenase (quinone) Homo sapiens 237-243 30599408-4 2019 In the present study, we synthesized and screened a series of Quinoline derivatives and evaluated their binding affinity for hnRNP K. quinoline 62-71 heterogeneous nuclear ribonucleoprotein K Homo sapiens 125-132 30738663-2 2019 We have designed 2-,4,-6-, and/or 7-substituted quinoline derivatives and predicted their hDHODH inhibitory activity based on 3D QSAR study on 45 substituted quinoline derivatives as hDHODH inhibitors, and also predicted toxicity. quinoline 158-167 dihydroorotate dehydrogenase (quinone) Homo sapiens 90-96 30738663-2 2019 We have designed 2-,4,-6-, and/or 7-substituted quinoline derivatives and predicted their hDHODH inhibitory activity based on 3D QSAR study on 45 substituted quinoline derivatives as hDHODH inhibitors, and also predicted toxicity. quinoline 158-167 dihydroorotate dehydrogenase (quinone) Homo sapiens 183-189 30698189-4 2019 Introduction of three methoxy substituents at the 5,6,7-positions of each quinoline moiety in BAPTQ specifically enhanced the fluorescence intensity of the Cd2+ complex, establishing the Cd2+-specific probe TriMeOBAPTQ (N,N,N",N"-tetrakis(5,6,7-trimethoxy-2-quinolylmethyl)-1,2-bis(2-aminophenoxy)ethane). quinoline 74-83 CD2 molecule Homo sapiens 156-159 29283317-2 2019 Results showed that 20 mg L-1 quinoline addition leading the ammonia and nitrite removal efficiency of the ABR reduced from about 90% to 40%. quinoline 30-39 immunoglobulin kappa variable 1-16 Homo sapiens 26-29 30698189-4 2019 Introduction of three methoxy substituents at the 5,6,7-positions of each quinoline moiety in BAPTQ specifically enhanced the fluorescence intensity of the Cd2+ complex, establishing the Cd2+-specific probe TriMeOBAPTQ (N,N,N",N"-tetrakis(5,6,7-trimethoxy-2-quinolylmethyl)-1,2-bis(2-aminophenoxy)ethane). quinoline 74-83 CD2 molecule Homo sapiens 187-190 30380447-0 2019 Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. quinoline 54-63 epidermal growth factor receptor Homo sapiens 121-125 30372901-0 2018 Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives. quinoline 112-121 fms related receptor tyrosine kinase 3 Homo sapiens 43-47 30360261-2 2019 During batch tests, the bioactivity of anammox granules in the presence of different quinoline concentrations was monitored, and the IC50 of quinoline was calculated to be 13.1 mg L-1 using a non-competitive inhibition model. quinoline 141-150 immunoglobulin kappa variable 1-16 Homo sapiens 180-183 30360261-3 2019 The response of anammox granules to pre-exposure to quinoline was dependent on metabolic status, and the presence of both quinoline and NO2--N had a rapid detrimental effect, resulting in a 64.5% decrease within 12 h. During continuous-flow experiments, the nitrogen removal rate (NRR) of the reactor decreased sharply within 3 days in the presence of 10 mg L-1 quinoline and then was restored to 2.6 kg N m-3 d-1. quinoline 122-131 immunoglobulin kappa variable 1-16 Homo sapiens 358-361 30360261-3 2019 The response of anammox granules to pre-exposure to quinoline was dependent on metabolic status, and the presence of both quinoline and NO2--N had a rapid detrimental effect, resulting in a 64.5% decrease within 12 h. During continuous-flow experiments, the nitrogen removal rate (NRR) of the reactor decreased sharply within 3 days in the presence of 10 mg L-1 quinoline and then was restored to 2.6 kg N m-3 d-1. quinoline 122-131 immunoglobulin kappa variable 1-16 Homo sapiens 358-361 30360261-5 2019 After cultivation and acclimation obtained by adding a medium level of quinoline to the influent, the anammox granule sludge was able to tolerate 10 mg L-1 quinoline in 178 days. quinoline 71-80 immunoglobulin kappa variable 1-16 Homo sapiens 152-155 30360261-5 2019 After cultivation and acclimation obtained by adding a medium level of quinoline to the influent, the anammox granule sludge was able to tolerate 10 mg L-1 quinoline in 178 days. quinoline 156-165 immunoglobulin kappa variable 1-16 Homo sapiens 152-155 30563725-0 2019 Design, synthesis, and biological evaluation of radioiodinated benzo[d]imidazole-quinoline derivatives for platelet-derived growth factor receptor beta (PDGFRbeta) imaging. quinoline 81-90 platelet derived growth factor receptor, beta polypeptide Mus musculus 107-151 30563725-0 2019 Design, synthesis, and biological evaluation of radioiodinated benzo[d]imidazole-quinoline derivatives for platelet-derived growth factor receptor beta (PDGFRbeta) imaging. quinoline 81-90 platelet derived growth factor receptor, beta polypeptide Mus musculus 153-162 30563725-2 2019 A series of benzo[d]imidazole-quinoline derivatives were designed and synthesized to develop radioiodinated compounds as PDGFRbeta-specific imaging probes. quinoline 30-39 platelet derived growth factor receptor, beta polypeptide Mus musculus 121-130 30500087-0 2019 Novel quinoline derivatives carrying nitrones/oximes nitric oxide donors: Design, synthesis, antiproliferative and caspase-3 activation activities. quinoline 6-15 caspase 3 Homo sapiens 115-124 30072500-2 2019 The recent development of quinoline-based PET tracers that act as FAP inhibitors (FAPIs) demonstrated promising results preclinically and already in a few clinical cases. quinoline 26-35 fibroblast activation protein alpha Homo sapiens 66-69 30428415-8 2019 Together, our findings support the antitumor potential of quinoline-chalcone derivatives for NSCLC and CML by inhibiting the PI3K/Akt/mTOR pathway. quinoline 58-67 AKT serine/threonine kinase 1 Homo sapiens 130-133 30428415-8 2019 Together, our findings support the antitumor potential of quinoline-chalcone derivatives for NSCLC and CML by inhibiting the PI3K/Akt/mTOR pathway. quinoline 58-67 mechanistic target of rapamycin kinase Homo sapiens 134-138 30372901-3 2018 The main aim of this study was evaluating cytotoxic effects of novel pyrimidocyanoacrylates and quinoline derivatives on FLT3 overexpressing cells. quinoline 96-105 fms related receptor tyrosine kinase 3 Homo sapiens 121-125 30204441-4 2018 Starting from a series of previously reported phenoxyquinazoline and quinoline based inhibitors of the tyrosine kinase PDGFRalpha, potency against a diverse panel of mutant KIT driven Ba/F3 cell lines was optimized, with a particular focus on reducing activity against a KDR driven cell model in order to limit the potential for hypertension commonly seen in second and third line GIST therapies. quinoline 69-78 platelet derived growth factor receptor, alpha polypeptide Mus musculus 119-129 30209037-0 2018 Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect. quinoline 49-58 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 14-19 30209037-0 2018 Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect. quinoline 49-58 aldehyde oxidase 1 Homo sapiens 62-78 30209037-1 2018 Some quinoline-containing c-Met kinase inhibitors are aldehyde oxidase (AO) substrates. quinoline 5-14 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 26-31 30209037-1 2018 Some quinoline-containing c-Met kinase inhibitors are aldehyde oxidase (AO) substrates. quinoline 5-14 aldehyde oxidase 1 Homo sapiens 54-70 30209037-1 2018 Some quinoline-containing c-Met kinase inhibitors are aldehyde oxidase (AO) substrates. quinoline 5-14 aldehyde oxidase 1 Homo sapiens 72-74 30209037-11 2018 Our finding could provide useful information for chemists to minimize potential AO liability when designing quinoline analogs. quinoline 108-117 aldehyde oxidase 1 Homo sapiens 80-82 30375667-7 2018 In particular, the quinoline derivative [11 C]QBA had the best binding properties in terms of high-brain localization to GluN2B-rich regions and specificity to the GluN2B subunit. quinoline 19-28 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 121-127 30375667-7 2018 In particular, the quinoline derivative [11 C]QBA had the best binding properties in terms of high-brain localization to GluN2B-rich regions and specificity to the GluN2B subunit. quinoline 19-28 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 164-170 30215145-1 2018 A quinoline functionalized two novel fluorescent Schiff bases, N-(quinolin-2-ylmethylene) anthracen-1-amine (SB1) and 2-(quinolin-2-ylmethyleneamino) benzene thiol (SB2) were synthesized and confirmed by using 1H NMR, IR and GC-MS techniques. quinoline 2-11 SH3KBP1 binding protein 1 Homo sapiens 109-112 30344731-1 2018 SGI-1027, a novel class of relatively stable, highly lipophilic quinoline-based small-molecule inhibitors of DNA methyltransferase enzymes (DNMTs), is able to inhibit DNMTs activity, and reactivate tumor suppressor genes. quinoline 64-73 semenogelin 1 Homo sapiens 0-3 30360426-7 2018 Accordingly, compound 5 represented a lead structure for the development of quinoline-based NF-kappaB inhibitors and this work added novel information on the understanding of the mechanism of action for bioactive sulfonyl-containing quinoline compounds against hepatocellular carcinoma. quinoline 76-85 nuclear factor kappa B subunit 1 Homo sapiens 92-101 30360426-7 2018 Accordingly, compound 5 represented a lead structure for the development of quinoline-based NF-kappaB inhibitors and this work added novel information on the understanding of the mechanism of action for bioactive sulfonyl-containing quinoline compounds against hepatocellular carcinoma. quinoline 233-242 nuclear factor kappa B subunit 1 Homo sapiens 92-101 30142564-0 2018 Quinoline containing chalcone derivatives as cholinesterase inhibitors and their in silico modeling studies. quinoline 0-9 butyrylcholinesterase Homo sapiens 45-59 29626119-0 2018 Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. quinoline 15-24 fibroblast activation protein alpha Homo sapiens 72-101 30215255-2 2018 This study involves the quinoline SPE2, 7-hydroxy-6-methoxyquinolin-2(1 H)-one, isolated from the EtOAc fraction of Spondias pinnata bark. quinoline 24-33 salivary protein electrophoretic 2 Mus musculus 34-38 30344914-0 2018 Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. quinoline 18-27 receptor interacting serine/threonine kinase 2 Homo sapiens 34-38 30344914-0 2018 Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. quinoline 18-27 ETS transcription factor ERG Homo sapiens 99-103 29628329-2 2018 Herein we report initial structure-activity relationships for the newly identified quinoline-based PPARalpha agonist, Y-0452. quinoline 83-92 peroxisome proliferator activated receptor alpha Homo sapiens 99-108 29626119-4 2018 Methods: FAPIs based on a quinoline structure were synthesized and characterized with respect to binding, internalization, and efflux in cells expressing human and murine FAP as well as CD26. quinoline 26-35 fibroblast activation protein Mus musculus 9-12 30117507-0 2018 Quinoline-galactose hybrids bind selectively with high affinity to a galectin-8 N-terminal domain. quinoline 0-9 galectin 8 Homo sapiens 69-79 29853337-2 2018 A structure-activity relationship study showed that the 1H-pyrrolo[3,2-h]quinoline scaffold was more favorable for 5-HT6R binding than the 1H-pyrrolo[2,3-f]quinoline one, suggesting dependence upon the type of condensation of the pyrrole and quinoline rings. quinoline 73-82 5-hydroxytryptamine receptor 6 Homo sapiens 115-121 30076329-0 2018 A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B. quinoline 6-15 autophagy related 4B cysteine peptidase Homo sapiens 86-91 29602046-0 2018 Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2/-5-LOX inhibition profile of some novel quinoline derivatives. quinoline 111-120 mitochondrially encoded cytochrome c oxidase I Homo sapiens 63-68 29602046-0 2018 Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2/-5-LOX inhibition profile of some novel quinoline derivatives. quinoline 111-120 lysyl oxidase Homo sapiens 74-77 29543459-7 2018 It is found that the cation within the HBA, namely, MTP, possesses favorable interactions with quinoline when compared to HBD or anion (Br). quinoline 95-104 metallothionein 1B Homo sapiens 52-55 29727569-4 2018 This effort led to the discovery of potent quinoline-based analogues 41 (DHODH IC50 = 9.71 +- 1.4 nM) and 43 (DHODH IC50 = 26.2 +- 1.8 nM). quinoline 43-52 dihydroorotate dehydrogenase (quinone) Homo sapiens 73-78 29727569-4 2018 This effort led to the discovery of potent quinoline-based analogues 41 (DHODH IC50 = 9.71 +- 1.4 nM) and 43 (DHODH IC50 = 26.2 +- 1.8 nM). quinoline 43-52 dihydroorotate dehydrogenase (quinone) Homo sapiens 110-115 29767973-0 2018 Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. quinoline 34-43 aldehyde dehydrogenase 1 family member A1 Homo sapiens 50-76 29767973-0 2018 Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. quinoline 34-43 aldehyde dehydrogenase 1 family member A1 Homo sapiens 78-85 29767973-3 2018 Herein, a newly designed series of quinoline-based analogs of ALDH1A1 inhibitors is described. quinoline 35-44 aldehyde dehydrogenase 1 family member A1 Homo sapiens 62-69 28784429-8 2018 FLAP inhibitors reviewed herein are classified into four sub-classes as the first-generation FLAP inhibitors (indole and quinoline derivatives), the second-generation FLAP inhibitors (diaryl-alkanes and biaryl amino-heteroarenes), the benzimidazole-containing FLAP inhibitors and other FLAP inhibitors with polypharmacology for easiness of the reader. quinoline 121-130 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 29649742-0 2018 Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. quinoline 66-75 purinergic receptor P2X 7 Homo sapiens 82-95 29649742-4 2018 However, because most of the quinolinone derivatives showed low inhibitory effects in an IL-1beta ELISA assay, the core structure was further modified to a quinoline skeleton with chloride or substituted phenyl groups. quinoline 156-165 interleukin 1 beta Homo sapiens 89-97 29991770-0 2018 Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRbeta) imaging probes. quinoline 30-39 platelet derived growth factor receptor beta Homo sapiens 55-99 29991770-0 2018 Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRbeta) imaging probes. quinoline 30-39 platelet derived growth factor receptor beta Homo sapiens 101-110 30288221-1 2018 Two small series of quinoline derivatives were designed starting from previously published quinoline derivatives 7a and b in order to obtain information about their interaction with the 5-HT4R binding site. quinoline 20-29 5-hydroxytryptamine receptor 4 Homo sapiens 186-192 30288221-1 2018 Two small series of quinoline derivatives were designed starting from previously published quinoline derivatives 7a and b in order to obtain information about their interaction with the 5-HT4R binding site. quinoline 91-100 5-hydroxytryptamine receptor 4 Homo sapiens 186-192 29566331-7 2018 We report that GMQ derivatives containing quinazoline and quinoline induced, as GMQ, an alkaline shift of the pH dependence of activation in ASIC3 and an acidic shift in ASIC1a. quinoline 58-67 acid sensing ion channel subunit 3 Homo sapiens 141-146 29897151-4 2018 New compounds based on the privileged adenosine triphosphate (ATP) site binder quinoline scaffold conjugated to glucose and galactosamine derivatives, which have significantly low cytotoxicity, but strong mTORC1 inhibitory activity at low micromolar concentrations, have been synthesized. quinoline 79-88 CREB regulated transcription coactivator 1 Mus musculus 205-211 29977388-3 2018 These new transformations displayed complete regioselectivity for the C-6 position of bipyridinones and the C-8 position of quinoline N-oxides and tolerated a broad range of functionalities, such as halogens, ethers, or trifluoromethyl groups. quinoline 124-133 homeobox C8 Homo sapiens 108-111 29649742-6 2018 In contrast to the quinolinone derivatives, the antagonistic effects of the quinoline compounds (16c and 17k) were paralleled by their ability to inhibit the release of the pro-inflammatory cytokine, IL-1beta, from LPS/IFN-gamma/BzATP-stimulated THP-1 cells (IC50 of 7 and 12 nM, respectively). quinoline 76-85 interleukin 1 beta Homo sapiens 200-208 29649742-6 2018 In contrast to the quinolinone derivatives, the antagonistic effects of the quinoline compounds (16c and 17k) were paralleled by their ability to inhibit the release of the pro-inflammatory cytokine, IL-1beta, from LPS/IFN-gamma/BzATP-stimulated THP-1 cells (IC50 of 7 and 12 nM, respectively). quinoline 76-85 interferon gamma Homo sapiens 219-228 29675524-1 2018 A ruthenium(ii) catalyzed remote C-5 alkylation of the quinoline ring of N-(quinolin-8-yl)benzamides with alkyl bromides via C-H bond activation is described. quinoline 55-64 complement C5 Homo sapiens 33-36 29343578-0 2018 A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. quinoline 6-15 bromodomain containing 4 Homo sapiens 16-20 29543459-8 2018 MTP here acts as a HBA and contributes to the hydrogen bonding with quinoline, which results in higher experimental selectivity values. quinoline 68-77 metallothionein 1B Homo sapiens 0-3 29992880-8 2018 CONCLUSION: Tacrine-quinoline hybrids 7a exhibited the highest activity towards hBChE (IC50 = 0.97 micromol) and 7d towards hAChE (IC50 = 0.32 micromol). quinoline 20-29 butyrylcholinesterase Homo sapiens 80-85 29247884-2 2018 In the present study, we explored the anti-colorectal cancer (CRC) activity of SL-1, a DNA-directed N-mustard-quinoline conjugate. quinoline 110-119 TATA-box binding protein associated factor, RNA polymerase I subunit A Homo sapiens 79-83 29247884-3 2018 The N-mustard moiety in SL-1 induced DNA strand breaks, interstrand cross-links (ICLs), G2/M arrest, and apoptosis, whereas its quinoline moiety preferentially directed SL-1 to target the selective guanine sequence 5"-G-G/C-N-G-C/T-3". quinoline 128-137 TATA-box binding protein associated factor, RNA polymerase I subunit A Homo sapiens 169-173 30068801-6 2018 Of the synthetic molecules, the quinoline derivative (10g) showed potent activity against TRAIL-resistant gastric adenocarcinoma cells. quinoline 32-41 TNF superfamily member 10 Homo sapiens 90-95 29992880-8 2018 CONCLUSION: Tacrine-quinoline hybrids 7a exhibited the highest activity towards hBChE (IC50 = 0.97 micromol) and 7d towards hAChE (IC50 = 0.32 micromol). quinoline 20-29 acetylcholinesterase (Cartwright blood group) Homo sapiens 124-129 29096097-0 2017 Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity. quinoline 6-15 epidermal growth factor receptor Homo sapiens 107-111 29675177-2 2018 Here we report a quinoline-derived ligand that enables the Pd(ii)-catalyzed olefination of the C(sp2)-H bond with simple aliphatic alkenes using a weakly coordinating monodentate amide auxiliary. quinoline 17-26 Sp2 transcription factor Homo sapiens 95-100 30747071-0 2018 Quinoline-based Protein-protein Interaction Inhibitors of LEDGF/p75 and HIV Integrase: An In Silico Study. quinoline 0-9 PC4 and SFRS1 interacting protein 1 Homo sapiens 58-67 29096097-3 2017 Quinazoline and quinoline derivatives are common anticancer intracellular inhibitors of EGFR kinase, and their optimization is an important issue for development of potent targeted anticancer agents. quinoline 16-25 epidermal growth factor receptor Homo sapiens 88-92 29259749-0 2017 Adding a Hydrogen Bond May Not Help: Naphthyridinone vs Quinoline Inhibitors of Macrophage Migration Inhibitory Factor. quinoline 56-65 macrophage migration inhibitory factor Homo sapiens 80-118 29259749-1 2017 Coordination of the ammonium group of Lys32 in the active site of human macrophage migration inhibitory factor (MIF) using a 1,7-naphthyridin-8-one instead of a quinoline is investigated. quinoline 161-170 macrophage migration inhibitory factor Homo sapiens 72-110 29259749-1 2017 Coordination of the ammonium group of Lys32 in the active site of human macrophage migration inhibitory factor (MIF) using a 1,7-naphthyridin-8-one instead of a quinoline is investigated. quinoline 161-170 macrophage migration inhibitory factor Homo sapiens 112-115 28985058-2 2017 We previously reported potent quinoline-based PDE5 inhibitors (PDE5Is) for the treatment of Alzheimer"s disease (AD). quinoline 30-39 phosphodiesterase 5A, cGMP-specific Mus musculus 46-50 28662962-6 2017 In addition, we generated GLP selective inhibitors bearing a quinoline core instead of the quinazoline core. quinoline 61-70 euchromatic histone lysine methyltransferase 1 Homo sapiens 26-29 28944420-3 2017 In this study, the anaerobic digestion of phenol (500 mg L-1) and quinoline (50 mg L-1) was investigated using an anaerobic baffled ceramic membrane bioreactor (ABCMBR). quinoline 66-75 immunoglobulin kappa variable 1-16 Homo sapiens 83-86 28797797-0 2017 Synthesis, estrogen receptor binding affinity and molecular docking of pyrimidine-piperazine-chromene and -quinoline conjugates. quinoline 107-116 estrogen receptor 1 Homo sapiens 11-28 28544981-0 2017 Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes. quinoline 53-62 phosphodiesterase 5A Homo sapiens 98-102 28544981-6 2017 Based on currently known PDE5 inhibitors, a series of novel fluorinated compounds bearing a quinoline core have been synthesised via multi-steps reaction pathways. quinoline 92-101 phosphodiesterase 5A Homo sapiens 25-29 28865280-1 2017 In this study synthesis and beta-glucuronidase inhibitory potential of 3/5/8 sulfonamide and 8-sulfonate derivatives of quinoline (1-40) are discussed. quinoline 120-129 glucuronidase beta Homo sapiens 28-46 28579121-2 2017 By applying the strategy to the previously identified templates, quinoline 4 and pyridines 16a, 16b, and 17 have been identified as subnanomolar or nanomolar inhibitors of human DPP-4. quinoline 65-74 dipeptidyl peptidase 4 Homo sapiens 178-183 28617670-5 2017 A highly sensitive and selective response in their absorption and emission towards Fe3+ over many other metal ions, including Cr3+ and Cu2+, was observed and may be the result of the ground state metal to ligand charge transfer effect from Fe3+ to quinoline ligands. quinoline 248-257 teratocarcinoma-derived growth factor 1 pseudogene 3 Homo sapiens 126-129 28621934-1 2017 A quinoline-based heptadentate ligand, N,N,N",N"-tetrakis(2-quinolylmethyl)-3-oxa-1,5-pentanediamine (TQOPEN), exhibits a fluorescence increase (ICd/I0 = 25, phiCd = 0.017) at 428 nm upon addition of 1 equiv of Cd2+. quinoline 2-11 CD2 molecule Homo sapiens 211-214 28621934-5 2017 Although the crystal structure of the TQOPEN-Cd2+ complex exhibits a six-coordinate metal center, in which one quinoline weakly interacts with the Cd center (Cd Nquinoline = 3.303(3) A), a 1H NMR study at 233 K suggests that all quinolines interact with the Cd center to form a symmetrical seven-coordinate structure in solution. quinoline 111-120 CD2 molecule Homo sapiens 45-48 28463487-2 2017 By incorporation of an indole or a quinoline moiety to the 9H-pyrimido[4,5-b]indole core, we identified a series of small molecules showing high binding affinities to BET proteins and low nanomolar potencies in inhibition of cell growth in acute leukemia cell lines. quinoline 35-44 delta/notch-like EGF repeat containing Mus musculus 167-170 28463515-3 2017 This approach resulted in quinazoline-quinoline derivatives as potent inhibitors of DNMT3A and DNMT1, some showing certain isoform selectivity. quinoline 38-47 DNA methyltransferase 3 alpha Homo sapiens 84-90 28463515-3 2017 This approach resulted in quinazoline-quinoline derivatives as potent inhibitors of DNMT3A and DNMT1, some showing certain isoform selectivity. quinoline 38-47 DNA methyltransferase 1 Homo sapiens 95-100 28868119-5 2017 Compound 3b containing the quinoline group showed the best activity with an IC50 value of 8.80 muM against AChE. quinoline 27-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-111 28359790-2 2017 Starting with a 4-substituted quinoline screening hit, SAR was conducted using a ALK5 binding model to understand the binding site and optimize activity. quinoline 30-39 sarcosine dehydrogenase Homo sapiens 55-58 28359790-2 2017 Starting with a 4-substituted quinoline screening hit, SAR was conducted using a ALK5 binding model to understand the binding site and optimize activity. quinoline 30-39 transforming growth factor beta receptor 1 Homo sapiens 81-85 28242549-5 2017 The results of in vitro biological activity evaluation, including beta-amyloid (Abeta) aggregation inhibition, cholinesterase inhibition, and antioxidant activity, showed that introduction of N-methyl in quinoline ring significantly improved the anti-AD potential of compounds. quinoline 204-213 amyloid beta (A4) precursor protein Mus musculus 80-85 28242549-5 2017 The results of in vitro biological activity evaluation, including beta-amyloid (Abeta) aggregation inhibition, cholinesterase inhibition, and antioxidant activity, showed that introduction of N-methyl in quinoline ring significantly improved the anti-AD potential of compounds. quinoline 204-213 butyrylcholinesterase Mus musculus 111-125 28523102-3 2017 The indole analogue 7e and quinoline analogue 13a displayed potent HDAC6 inhibitory activity (IC50, 11 and 2.8 nM) and excellent selectivity against HDAC1. quinoline 27-36 histone deacetylase 6 Mus musculus 67-72 28523102-3 2017 The indole analogue 7e and quinoline analogue 13a displayed potent HDAC6 inhibitory activity (IC50, 11 and 2.8 nM) and excellent selectivity against HDAC1. quinoline 27-36 histone deacetylase 1 Mus musculus 149-154 28804615-6 2017 Docking study showed that this quinoline derivative could inhibit COX-2 enzyme strongly. quinoline 31-40 cytochrome c oxidase II, mitochondrial Mus musculus 66-71 28359327-1 2017 BACKGROUND: 18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). quinoline 29-38 microtubule associated protein tau Homo sapiens 47-50 28979307-0 2017 QSAR Modeling of COX -2 Inhibitory Activity of Some Dihydropyridine and Hydroquinoline Derivatives Using Multiple Linear Regression (MLR) Method. quinoline 72-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-23 28286419-0 2017 Dual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer cells. quinoline 61-70 mitogen-activated protein kinase 1 Homo sapiens 14-51 28286419-0 2017 Dual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer cells. quinoline 61-70 mitogen-activated protein kinase 1 Homo sapiens 53-56 27866818-1 2016 A novel series of potent quinoline-based human H1 and H3 bivalent histamine receptor antagonists, suitable for intranasal administration for the potential treatment of allergic rhinitis associated nasal congestion, were identified. quinoline 25-34 H1.5 linker histone, cluster member Homo sapiens 47-84 27981329-1 2017 A quinoline-based heptadentate ligand, N,N,N",N"-tetrakis(2-quinolylmethyl)-2,6-bis(aminomethyl)pyridine (TQLN), exhibits a Zn2+-specific fluorescence increase at 428 nm, which is assigned to excimer emission (IZn/I0 = 38, ICd/IZn = 24%, phiZn = 0.069). quinoline 2-11 N-acetylglucosamine-1-phosphate transferase subunits alpha and beta Homo sapiens 223-226 27456944-0 2017 Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE2. quinoline 31-40 prostaglandin-endoperoxide synthase 2 Homo sapiens 128-133 28068604-5 2017 We found that quinoline derivatives 3a and 4 were the most potent compounds within this series, both with mean EC50 values of 0.8 muM, which represents a potency 5 times that of mefloquine. quinoline 14-23 latexin Homo sapiens 130-133 28073608-1 2017 A new series of quinoline analogues was designed and synthesized as Hsp90 inhibitors. quinoline 16-25 heat shock protein 90 alpha family class A member 1 Homo sapiens 68-73 28059409-0 2017 In vivo photoacoustic tumor tomography using a quinoline-annulated porphyrin as NIR molecular contrast agent. quinoline 47-56 NOC2 like nucleolar associated transcriptional repressor Mus musculus 80-83 28059409-2 2017 We previously demonstrated the ability of quinoline-annulated porphyrins to act as an in vitro NIR photoacoustic imaging (PAI) contrast agent. quinoline 42-51 NOC2 like nucleolar associated transcriptional repressor Mus musculus 95-98 28059409-3 2017 The solubility of the quinoline-annulated porphyrin derivative in serum now allowed the assessment of the efficacy of the PEGylated derivative as an in vivo NIR contrast agent for the PAI of an implanted tumor in a mouse model. quinoline 22-31 NOC2 like nucleolar associated transcriptional repressor Mus musculus 157-160 28036396-0 2016 A 2D-QSAR and Grid-Independent Molecular Descriptor (GRIND) Analysis of Quinoline-Type Inhibitors of Akt2: Exploration of the Binding Mode in the Pleckstrin Homology (PH) Domain. quinoline 72-81 AKT serine/threonine kinase 2 Homo sapiens 101-105 28036396-6 2016 Therefore, in this study, various in silico tools were utilized to explore the hypothesis that quinoline-type inhibitors bind in the Akt2 PH domain. quinoline 95-104 AKT serine/threonine kinase 2 Homo sapiens 133-137 27541261-2 2016 To develop potent TTR amyloidogenesis inhibitors, we have designed and synthesized a focused library of quinoline derivatives by Pd-catalyzed coupling reaction and by the Horner-Wadsworth-Emmons reaction. quinoline 104-113 transthyretin Homo sapiens 18-21 27541261-4 2016 Among these quinoline derivatives, compound 14c exhibited the most potent anti-TTR fibril formation activity in the screening studies, with IC50 values of 1.49 muM against WT-TTR and 1.63 muM against more amyloidogenic V30 M TTR mutant. quinoline 12-21 transthyretin Homo sapiens 79-82 27084847-0 2016 The TLR7 agonist imiquimod induces bronchodilation via a nonneuronal TLR7-independent mechanism: a possible role for quinoline in airway dilation. quinoline 117-126 toll like receptor 7 Homo sapiens 4-8 27541261-4 2016 Among these quinoline derivatives, compound 14c exhibited the most potent anti-TTR fibril formation activity in the screening studies, with IC50 values of 1.49 muM against WT-TTR and 1.63 muM against more amyloidogenic V30 M TTR mutant. quinoline 12-21 WT1 transcription factor Homo sapiens 172-184 27541261-4 2016 Among these quinoline derivatives, compound 14c exhibited the most potent anti-TTR fibril formation activity in the screening studies, with IC50 values of 1.49 muM against WT-TTR and 1.63 muM against more amyloidogenic V30 M TTR mutant. quinoline 12-21 transthyretin Homo sapiens 175-178 27541261-8 2016 Taken together, the novel quinoline derivatives could potentially be explored as potential drug candidates to treat the human TTR amyloidosis. quinoline 26-35 transthyretin Homo sapiens 126-129 27533734-1 2016 An unprecedented C(8)-H bond allylation of quinoline with allyl carbonate and allyl alcohol catalyzed by Cp*Co(III) using a traceless directing group via beta-oxygen and beta-hydroxy elimination is described. quinoline 43-52 mitochondrially encoded cytochrome c oxidase III Homo sapiens 108-115 27568085-2 2016 These compounds incorporate the key elements utilized in quinoline-based ALLINIs for binding to the IN dimer interface at the principal LEDGF/p75 binding pocket. quinoline 57-66 PC4 and SFRS1 interacting protein 1 Homo sapiens 136-145 27568085-3 2016 The most potent of these compounds displayed good activity in the LEDGF/p75 dependent integration assay (IC50=4.5muM) and, as predicted based on the geometry of the five- versus six-membered ring, retained activity against the A128T IN mutant that confers resistance to many quinoline-based ALLINIs. quinoline 275-284 PC4 and SFRS1 interacting protein 1 Homo sapiens 66-75 27527129-2 2016 Quinoline-based azathilones with the side chain N-atom in the meta-position to the C15 atom in the macrocycle are highly potent inhibitors of cancer cell growth in vitro. quinoline 0-9 placenta associated 8 Homo sapiens 83-86 27527129-3 2016 In contrast, shifting the quinoline nitrogen to the position para to C15 leads to a ca. quinoline 26-35 placenta associated 8 Homo sapiens 69-72 27110797-0 2016 Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. quinoline 38-47 thyroid stimulating hormone receptor Mus musculus 59-62 27110797-0 2016 Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. quinoline 38-47 phosphodiesterase 5A, cGMP-specific Mus musculus 74-93 27110797-0 2016 Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. quinoline 38-47 phosphodiesterase 5A, cGMP-specific Mus musculus 95-99 27110797-5 2016 A quinoline-based lead compound has been structurally modified resulting in the fluoroethoxymethyl derivative ICF24027 with high inhibitory activity towards PDE5 (IC50 = 1.86 nM). quinoline 2-11 phosphodiesterase 5A, cGMP-specific Mus musculus 157-161 26564153-0 2016 Quinoline-Based Compound BPIQ Exerts Anti-Proliferative Effects on Human Retinoblastoma Cells via Modulating Intracellular Reactive Oxygen Species. quinoline 0-9 RB transcriptional corepressor 1 Homo sapiens 73-87 26979485-0 2016 Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors. quinoline 39-48 Pim-1 proto-oncogene, serine/threonine kinase Homo sapiens 106-111 26861273-5 2016 In this work, we reported the synthesis and biological evaluation of a library of new tacrine-donepezil hybrids, as a potential dual binding site AChE inhibitor, containing a triazole-quinoline system. quinoline 184-193 acetylcholinesterase (Cartwright blood group) Homo sapiens 146-150 26840365-1 2016 As a continuation of previous work on quinoline derivatives, which showed some preference (2-3 times) for the alpha7 with respect to alpha4beta2 acetylcholine nicotinic receptors (nAChRs), we synthesized a series of novel azabicyclic or diazabicyclic compounds carrying a quinoline or isoquinoline ring, with the aim of searching for more selective alpha7 nAChR compounds. quinoline 38-47 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 180-185 26502898-5 2016 Naphthyl and quinolin derivatives showed a good activation of PPARalpha; noteworthy, optically active naphthyl derivatives activated PPARalpha better than corresponding parent compound. quinoline 13-21 peroxisome proliferator activated receptor alpha Homo sapiens 62-71 26502898-5 2016 Naphthyl and quinolin derivatives showed a good activation of PPARalpha; noteworthy, optically active naphthyl derivatives activated PPARalpha better than corresponding parent compound. quinoline 13-21 peroxisome proliferator activated receptor alpha Homo sapiens 133-142 26637323-1 2016 In a preceding work with dopant assisted-atmospheric pressure photoionization (DA-APPI), an abundant ion at [M + 77](+) was observed in the spectra of pyridine and quinoline with chlorobenzene dopant. quinoline 164-173 amyloid beta precursor protein Homo sapiens 82-86 26861273-9 2016 These results are quite interesting since the triazole-quinoline system is a new structural scaffold for AChE inhibitors. quinoline 55-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 105-109 26939394-7 2016 CONCLUSION: The quinoline derivative PQ1 can promote the gap junction communication of prostate cancer PC3 cells and enhance the killing effect of cisplatin on PC3 cells by upregulating the expressions of Cx43 mRNA and protein. quinoline 16-25 gap junction protein alpha 1 Homo sapiens 205-209 26575418-1 2015 Scandium-triflate (Sc(OTf)3) was introduced for the first time on metal-organic frameworks (MOFs), to utilize acidic Sc(OTf)3 for adsorptive desulfurization and denitrogenation of fuel containing benzothiophene (BT), dibenzothiophene (DBT), quinoline (QUI), and indole (IND). quinoline 241-250 POU class 5 homeobox 1 Homo sapiens 19-27 26596710-0 2015 Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation. quinoline 19-28 mechanistic target of rapamycin kinase Homo sapiens 35-39 26596710-1 2015 A series of quinoline derivatives featuring the novelty of introducing intra-molecular hydrogen bonding scaffold (iMHBS) were designed, synthesized and biologically evaluated for their mTOR inhibitory activity, as well as anti-proliferative efficacies against HCT-116, PC-3 and MCF-7 cell lines. quinoline 12-21 mechanistic target of rapamycin kinase Homo sapiens 185-189 26596710-1 2015 A series of quinoline derivatives featuring the novelty of introducing intra-molecular hydrogen bonding scaffold (iMHBS) were designed, synthesized and biologically evaluated for their mTOR inhibitory activity, as well as anti-proliferative efficacies against HCT-116, PC-3 and MCF-7 cell lines. quinoline 12-21 proprotein convertase subtilisin/kexin type 1 Homo sapiens 260-273 26608552-1 2016 A novel series of EP4 antagonists, based on a quinoline scaffold, has been discovered. quinoline 46-55 prostaglandin E receptor 4 Homo sapiens 18-21 26575418-1 2015 Scandium-triflate (Sc(OTf)3) was introduced for the first time on metal-organic frameworks (MOFs), to utilize acidic Sc(OTf)3 for adsorptive desulfurization and denitrogenation of fuel containing benzothiophene (BT), dibenzothiophene (DBT), quinoline (QUI), and indole (IND). quinoline 241-250 POU class 5 homeobox 1 Homo sapiens 117-125 26575418-1 2015 Scandium-triflate (Sc(OTf)3) was introduced for the first time on metal-organic frameworks (MOFs), to utilize acidic Sc(OTf)3 for adsorptive desulfurization and denitrogenation of fuel containing benzothiophene (BT), dibenzothiophene (DBT), quinoline (QUI), and indole (IND). quinoline 252-255 POU class 5 homeobox 1 Homo sapiens 19-27 26575418-1 2015 Scandium-triflate (Sc(OTf)3) was introduced for the first time on metal-organic frameworks (MOFs), to utilize acidic Sc(OTf)3 for adsorptive desulfurization and denitrogenation of fuel containing benzothiophene (BT), dibenzothiophene (DBT), quinoline (QUI), and indole (IND). quinoline 252-255 POU class 5 homeobox 1 Homo sapiens 117-125 26463131-3 2015 The results of the SAR developed highlight the relationship between the sulfonamide and quinoline nitrogen, while also suggesting that an aryl substituent at the 5-position of the quinoline ring contributes to the potency in the interaction assay. quinoline 88-97 sarcosine dehydrogenase Homo sapiens 19-22 26463131-3 2015 The results of the SAR developed highlight the relationship between the sulfonamide and quinoline nitrogen, while also suggesting that an aryl substituent at the 5-position of the quinoline ring contributes to the potency in the interaction assay. quinoline 180-189 sarcosine dehydrogenase Homo sapiens 19-22 26453006-0 2015 Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5"-phosphatase (SHIP). quinoline 36-45 inositol polyphosphate-5-phosphatase D Homo sapiens 70-108 26453006-0 2015 Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5"-phosphatase (SHIP). quinoline 36-45 inositol polyphosphate-5-phosphatase D Homo sapiens 110-114 26491978-0 2015 Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. quinoline 134-143 lysine demethylase 4A Homo sapiens 47-53 26453006-2 2015 Utilizing high-throughput screening, two quinoline small molecules (NSC13480 and NSC305787) that inhibit SHIP1 enzymatic activity were discovered. quinoline 41-50 inositol polyphosphate-5-phosphatase D Homo sapiens 105-110 26453006-5 2015 These structure activity studies determined that an amine tethered to the quinoline core is required for SHIP inhibition. quinoline 74-83 inositol polyphosphate-5-phosphatase D Homo sapiens 105-109 26430878-3 2015 Seven F-18 labeled compounds [(18)F]18a-e, [(18)F]18g, and [(18)F]20a were radiosynthesized by (18)F-introduction onto the quinoline rather than the pyrazole moiety of the MP-10 pharmacophore and performed in vivo evaluation. quinoline 123-132 mastermind like domain containing 1 Homo sapiens 6-10 25897210-15 2015 CONCLUSION: Collectively, this study reports for the first time the anticancer effects of CQ and NQ against CCA cells, and highlights new insights into the mechanism of actions of the quinoline-based compounds to disrupt FoxM1 signaling. quinoline 184-193 forkhead box M1 Homo sapiens 221-226 26381451-4 2015 Herein we report the discovery, by an integrated lead finding approach, of two new chemical classes of allosteric FPPS inhibitors that belong to the salicylic acid and quinoline chemotypes. quinoline 168-177 farnesyl diphosphate synthase Homo sapiens 114-118 26159576-0 2015 Screening of quinoline, 1,3-benzoxazine, and 1,3-oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an in silico binding mode analysis. quinoline 13-22 methionyl-tRNA synthetase 1 Homo sapiens 96-121 26006257-2 2015 In the search for new HPPD inhibitors with novel scaffolds, triketone-quinoline hybrids were designed and subsequently optimized on the basis of the structure-activity relationship (SAR) studies. quinoline 70-79 4-hydroxyphenylpyruvate dioxygenase 1 Zea mays 22-26 25923513-1 2015 A series of quinoline derivatives was synthesized and biologically evaluated as Enhancer of Zeste Homologue 2 (EZH2) inhibitors. quinoline 12-21 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 80-109 25923513-1 2015 A series of quinoline derivatives was synthesized and biologically evaluated as Enhancer of Zeste Homologue 2 (EZH2) inhibitors. quinoline 12-21 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 111-115 25923513-3 2015 Due to the low molecular weight and the fact that no quinoline derivative has been reported as an EZH2 inhibitor, this compound could serve as a lead compound for further optimization. quinoline 53-62 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 98-102 25707447-1 2015 A novel CBr4-mediated dehydrogenative Povarov/aromatization tandem reaction of glycine derivatives with alkenes, leading to complex quinoline derivatives, and a CBr4-mediated dehydrogenative C-H functionalization of N-aryl tetrahydroisoquinolines with nucleophiles to form C-C and C-P bonds are reported. quinoline 132-141 carbonyl reductase 4 Homo sapiens 8-12 25897210-0 2015 Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells. quinoline 0-9 forkhead box M1 Homo sapiens 80-85 25789987-0 2015 Quinoline compound KM11073 enhances BMP-2-dependent osteogenic differentiation of C2C12 cells via activation of p38 signaling and exhibits in vivo bone forming activity. quinoline 0-9 bone morphogenetic protein 2 Mus musculus 36-41 25789987-0 2015 Quinoline compound KM11073 enhances BMP-2-dependent osteogenic differentiation of C2C12 cells via activation of p38 signaling and exhibits in vivo bone forming activity. quinoline 0-9 mitogen-activated protein kinase 14 Mus musculus 112-115 25515954-2 2015 Replacement of pyridine ring of 1 with N-methyl pyridone ring drastically improved CYP3A4 inhibition, and further optimization of these quinoline analogues identified 1-methyl-5-(1-methyl-3-{[4-(quinolin-2-yl)phenoxy]methyl}-1H-pyrazol-4-yl)pyridin-2(1H)-one (42b), which showed potent PDE10A inhibitory activity and a good CYP3A4 inhibition profile. quinoline 136-145 phosphodiesterase 10A Mus musculus 286-292 25503645-0 2015 Identification of benzenesulfonamide quinoline derivatives as potent HIV-1 replication inhibitors targeting Rev protein. quinoline 37-46 Rev Human immunodeficiency virus 1 108-111 24903887-0 2015 Structural basis for low-affinity binding of non-R2 carboxylate-substituted tricyclic quinoline analogs to CK2alpha: comparative molecular dynamics simulation studies. quinoline 86-95 casein kinase 2 alpha 2 Homo sapiens 107-115 25832358-0 2015 A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells. quinoline 8-17 mechanistic target of rapamycin kinase Homo sapiens 42-46 25832358-0 2015 A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells. quinoline 8-17 AKT serine/threonine kinase 1 Homo sapiens 98-101 25832358-0 2015 A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells. quinoline 8-17 mechanistic target of rapamycin kinase Homo sapiens 102-106 25453790-0 2014 "Naked-eye" quinoline-based "reactive" sensor for recognition of Hg2+ ion in aqueous solution. quinoline 12-21 polycystin 1, transient receptor potential channel interacting pseudogene 2 Homo sapiens 65-68 24929289-1 2014 In continuation of our research for novel human dihydroorotate dehydrogenase (hDHODH) inhibitors, herein we reported design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives. quinoline 187-196 dihydroorotate dehydrogenase (quinone) Homo sapiens 78-84 25257526-0 2014 Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method. quinoline 39-48 melanin concentrating hormone receptor 1 Homo sapiens 76-81 25257526-2 2014 In the present work, the up-to-date largest set of 181 quinoline/quinazoline derivatives as MCHR1 antagonists was subjected to both ligand- and receptor-based three-dimensional quantitative structure-activity (3D-QSAR) analysis applying comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). quinoline 55-64 melanin concentrating hormone receptor 1 Homo sapiens 92-97 24837237-7 2014 Direct interactions between quinolines and the oxygenases of the pathway (especially with the indoleamine (2,3)-dioxygenase and kynurenine-monoxygenase) and indirect influences via the interferon-gamma induced breakdown of tryptophane are discussed, as well as the modifying effect of the already existing neurotoxicity of the single quinoline related drug used. quinoline 28-37 interferon gamma Homo sapiens 185-201 24813882-5 2014 For MAO B, the quinoline system was hosted at the cavity entrance whereas for MAO A this system occupied the substrate cavity. quinoline 15-24 monoamine oxidase B Mus musculus 4-9 24666182-1 2014 Monoselective gamma-C-H olefination and carbonylation of aliphatic acids has been accomplished by using a combination of a quinoline-based ligand and a weakly coordinating amide directing group. quinoline 123-132 interleukin 2 receptor subunit gamma Homo sapiens 14-21 24747187-0 2014 Synthesis, characterization, theoretical, anti-bacterial and molecular docking studies of quinoline based chalcones as a DNA gyrase inhibitor. quinoline 90-99 DNA topoisomerase II alpha Homo sapiens 121-131 24874515-3 2014 However, dissecting the exact mechanism of action of the quinoline-based ALLINIs has been complicated by the multifunctional nature of these inhibitors because they both inhibit IN binding with its cofactor LEDGF/p75 and promote aberrant IN multimerization with similar potencies in vitro. quinoline 57-66 PC4 and SFRS1 interacting protein 1 Homo sapiens 207-216 24618302-2 2014 The optimization of the initial lead compound 7 based on in vitro and in vivo activity led to the discovery of potent indoline and quinoline classes of DGAT1 inhibitors. quinoline 131-140 diacylglycerol O-acyltransferase 1 Homo sapiens 152-157 24630412-0 2014 Schiff"s base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors. quinoline 53-62 epidermal growth factor receptor Homo sapiens 116-120 24504685-0 2014 Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells. quinoline 0-9 E1A binding protein p300 Homo sapiens 16-20 24556381-2 2014 Evaluation of the inhibitory activity led to the identification of two quinoline inhibitors of cholesterol esterase. quinoline 71-80 carboxyl ester lipase Homo sapiens 95-115 24246954-0 2014 Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors. quinoline 53-62 farnesyl diphosphate synthase Homo sapiens 82-86 24246954-4 2014 RESULTS: We report our syntheses of a series of quinoline derivatives as new FPPS inhibitors possibly targeting the allosteric site of the enzyme. quinoline 48-57 farnesyl diphosphate synthase Homo sapiens 77-81 24678024-0 2014 Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. quinoline 96-105 chromogranin B Homo sapiens 112-115 24678024-1 2014 Quinoline derivative SGI-1027 (N-(4-(2-amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-ylamino)benzamide) was first described in 2009 as a potent inhibitor of DNA methyltransferase (DNMT) 1, 3A and 3B. quinoline 0-9 chromogranin B Homo sapiens 21-24 24678024-1 2014 Quinoline derivative SGI-1027 (N-(4-(2-amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-ylamino)benzamide) was first described in 2009 as a potent inhibitor of DNA methyltransferase (DNMT) 1, 3A and 3B. quinoline 0-9 DNA methyltransferase 1 Homo sapiens 167-208 24678024-2 2014 Based on molecular modeling studies, performed using the crystal structure of Haemophilus haemolyticus cytosine-5 DNA methyltransferase (MHhaI C5 DNMT), which suggested that the quinoline and the aminopyridimine moieties of SGI-1027 are important for interaction with the substrates and protein, we designed and synthesized 25 derivatives. quinoline 178-187 chromogranin B Homo sapiens 224-227 24485123-1 2014 A series of novel quinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) in vitro. quinoline 18-27 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 149-154 24753636-2 2014 As investigated by 1H NMR, the receptor forms both 1:1 and 1:2 complex yielding the binding constants of 2.32(3) (in log beta1 ) and 4.39(4) (in log beta2 ), respectively; where quinoline groups are protonated by the fluoride-induced proton transfer from the solution to the host molecule. quinoline 178-187 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 121-126 24753636-2 2014 As investigated by 1H NMR, the receptor forms both 1:1 and 1:2 complex yielding the binding constants of 2.32(3) (in log beta1 ) and 4.39(4) (in log beta2 ), respectively; where quinoline groups are protonated by the fluoride-induced proton transfer from the solution to the host molecule. quinoline 178-187 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 149-154 24332088-0 2014 Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor. quinoline 60-69 cyclin dependent kinase 2 Homo sapiens 35-39 25202762-1 2014 Site-selective C-H borylation of quinoline derivatives at the C8 position has been achieved by using a heterogeneous Ir catalyst system based on a silica-supported cage-type monophosphane ligand SMAP. quinoline 33-42 bromodomain containing 8 Homo sapiens 195-199 24332088-0 2014 Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor. quinoline 60-69 cyclin A2 Homo sapiens 44-52 24012712-1 2013 Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. quinoline 14-23 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 119-124 24211622-1 2014 A new Co(I) one-dimensional coordination polymer [Co(SCN)(ql)]n (ql=quinoline) (1) has been synthesized and characterized by IR, elemental analysis, TG technique and X-ray crystallography. quinoline 68-77 mitochondrially encoded cytochrome c oxidase I Homo sapiens 6-11 24039190-0 2013 Quinoline carboxamide-type ABCG2 modulators: indole and quinoline moieties as anilide replacements. quinoline 56-65 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-32 25450629-0 2014 Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors. quinoline 42-51 phosphodiesterase 10A Mus musculus 67-88 25230231-0 2014 Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines. quinoline 0-9 calcitonin related polypeptide alpha Homo sapiens 85-116 25230231-10 2014 We propose that quinoline derivatives possess inhibitory activity by disturbing CGRP binding in the trigeminovascular system and may be considered for further preclinical appraisal for the treatment of migraines. quinoline 16-25 calcitonin related polypeptide alpha Homo sapiens 80-84 23517028-2 2013 Subsequent hit to lead follow-up confirmed the activity of the chemotype, and a structure-based design approach using protein-ligand crystal structures of the beta1AR resulted in the identification of several fragments that bound with higher affinity, including indole 19 and quinoline 20. quinoline 276-285 adrenoceptor beta 1 Homo sapiens 159-166 23714018-0 2013 Development of docking-based 3D QSAR models for the design of substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors. quinoline 74-83 dihydroorotate dehydrogenase (quinone) Homo sapiens 135-141 23658734-3 2013 Recently, a novel class of compounds, 1,8-naphthyridine, pyridine and quinoline derivatives have been demonstrated to show high CB2 receptor selectivity and affinity versus the CB1 receptor. quinoline 70-79 cannabinoid receptor 2 Homo sapiens 128-131 23584545-2 2013 The HT29 cell line was more refractory to the cytotoxic activity of some compounds, meanwhile all the quinoline derivatives except one displayed high to moderate activity against MDA-MB231 with IC50 values ranging between 4.6 and 48.2 muM. quinoline 102-111 latexin Homo sapiens 235-238 23658734-3 2013 Recently, a novel class of compounds, 1,8-naphthyridine, pyridine and quinoline derivatives have been demonstrated to show high CB2 receptor selectivity and affinity versus the CB1 receptor. quinoline 70-79 cannabinoid receptor 1 Homo sapiens 177-180 23159484-4 2013 This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-alpha converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists. quinoline 48-57 phosphodiesterase 4A Homo sapiens 109-128 23407148-3 2013 Photocatalytic evaluation demonstrated that the as-synthesized TiO2 nanoparticles possess excellent quinoline degradation performance (a 2.33x10(-2)min(-1) apparent reaction rate constant comparing to 1.22x10(-2)min(-1) for P25) and recycle stability (the photocatalytic activity remained 96.6% of the initial activity after four cycles of repetitive uses). quinoline 100-109 tubulin polymerization promoting protein Homo sapiens 224-227 23159484-4 2013 This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-alpha converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists. quinoline 48-57 phosphodiesterase 4A Homo sapiens 130-134 23159484-4 2013 This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-alpha converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists. quinoline 48-57 ADAM metallopeptidase domain 17 Homo sapiens 140-186 23159484-4 2013 This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-alpha converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists. quinoline 48-57 ADAM metallopeptidase domain 17 Homo sapiens 188-192 23159484-4 2013 This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-alpha converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists. quinoline 48-57 transient receptor potential cation channel subfamily V member 1 Homo sapiens 206-246 23159484-4 2013 This review focuses on the discovery of various quinoline derivatives as inhibitors of cyclooxygenase (COX), phosphodiesterase 4 (PDE4) and tumour necrosis factor-alpha converting enzyme (TACE), along with transient receptor potential vanilloid 1 (TRPV1) antagonists. quinoline 48-57 transient receptor potential cation channel subfamily V member 1 Homo sapiens 248-253 23862618-1 2013 Quinoline-based small molecules have been explored and being developed as anti-inflammatory agents targeting several pharmacological targets namely Phosphodiesterase 4 (PDE4), Transient Receptor Potential Vanilloid 1 (TRPV1), TNF-alpha converting enzyme (TACE) and Cyclooxygenase (COX). quinoline 0-9 phosphodiesterase 4A Homo sapiens 148-167 23333207-1 2013 We described here the synthesis and biological evaluation of mGluR5 antagonists containing a quinoline ring structure. quinoline 93-102 glutamate receptor, ionotropic, kainate 1 Mus musculus 61-67 23672025-0 2013 [Design, synthesis and cholinesterase inhibitory activity of quinoline-polyamine conjugates]. quinoline 61-70 butyrylcholinesterase Homo sapiens 23-37 23354020-0 2013 Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis. quinoline 36-45 phosphodiesterase 10A Homo sapiens 61-67 23354020-2 2013 In the present work, the inhibition mechanism of 116 structurally diverse quinoline derivatives as PDE10A inhibitors was explored by 3D-QSAR, molecular docking and molecular dynamics (MD) simulations. quinoline 74-83 phosphodiesterase 10A Homo sapiens 99-105 23862618-1 2013 Quinoline-based small molecules have been explored and being developed as anti-inflammatory agents targeting several pharmacological targets namely Phosphodiesterase 4 (PDE4), Transient Receptor Potential Vanilloid 1 (TRPV1), TNF-alpha converting enzyme (TACE) and Cyclooxygenase (COX). quinoline 0-9 phosphodiesterase 4A Homo sapiens 169-173 23862618-1 2013 Quinoline-based small molecules have been explored and being developed as anti-inflammatory agents targeting several pharmacological targets namely Phosphodiesterase 4 (PDE4), Transient Receptor Potential Vanilloid 1 (TRPV1), TNF-alpha converting enzyme (TACE) and Cyclooxygenase (COX). quinoline 0-9 transient receptor potential cation channel subfamily V member 1 Homo sapiens 176-216 23862618-1 2013 Quinoline-based small molecules have been explored and being developed as anti-inflammatory agents targeting several pharmacological targets namely Phosphodiesterase 4 (PDE4), Transient Receptor Potential Vanilloid 1 (TRPV1), TNF-alpha converting enzyme (TACE) and Cyclooxygenase (COX). quinoline 0-9 transient receptor potential cation channel subfamily V member 1 Homo sapiens 218-223 23862618-1 2013 Quinoline-based small molecules have been explored and being developed as anti-inflammatory agents targeting several pharmacological targets namely Phosphodiesterase 4 (PDE4), Transient Receptor Potential Vanilloid 1 (TRPV1), TNF-alpha converting enzyme (TACE) and Cyclooxygenase (COX). quinoline 0-9 ADAM metallopeptidase domain 17 Homo sapiens 226-253 23862618-1 2013 Quinoline-based small molecules have been explored and being developed as anti-inflammatory agents targeting several pharmacological targets namely Phosphodiesterase 4 (PDE4), Transient Receptor Potential Vanilloid 1 (TRPV1), TNF-alpha converting enzyme (TACE) and Cyclooxygenase (COX). quinoline 0-9 ADAM metallopeptidase domain 17 Homo sapiens 255-259 23555703-10 2013 Furthermore, we demonstrated that the local application of a CYP inhibitor on rat olfactory epithelium increased EOG responses elicited by quinoline and coumarin. quinoline 139-148 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 61-64 22953930-0 2012 Study on the interaction of food colourant quinoline yellow with bovine serum albumin by spectroscopic techniques. quinoline 43-52 albumin Homo sapiens 72-85 22499396-0 2012 A novel quinoline-based two-photon fluorescent probe for detecting Cd2+ in vitro and in vivo. quinoline 8-17 CD2 molecule Homo sapiens 67-70 22967810-3 2012 This study of the structure-activity relationship of KNT-127 derivatives focused on the introduction of substituents onto the 5"-, 6"-, 7"- or 8"-position of the quinoline ring and revealed that many derivatives with 5"- or 8"-substituents showed high affinities and selectivities for the delta receptor. quinoline 162-171 kinectin 1 Homo sapiens 53-56 23007687-1 2012 In order to evaluate quinoline as a remote sensitiser, we have prepared a DTPA based ligand, H3L, bearing quinoline bisamide arms for the complexation of a range of lanthanide(III) ions to give the neutral complexes LnLwhere Ln(3+) = Y(3+), Eu(3+), Sm(3+), Tb(3+), Er(3+), Yb(3+), Nd(3+), Gd(3+). quinoline 21-30 H3 clustered histone 2 Homo sapiens 93-96 23047228-1 2012 The synthesis of quinoline derivatives, designed to interact with Bcl-x(L), and to inhibit its interaction with pro-apoptotic partners, is described and their biological effects investigated. quinoline 17-26 BCL2-like 1 Mus musculus 66-71 22309911-0 2012 Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. quinoline 55-64 epidermal growth factor receptor Homo sapiens 156-160 22590246-2 2012 The dihedral angles between the carboxyl groups and the benzene ring are 64.02 (9) and 21.67 (9) , the larger angle being associated with an intra-molecular N-H O(carbox-yl) hydrogen bond, resulting from proton transfer from the carb-oxy-lic acid group to the quinoline N atom and giving an S(9) ring motif. quinoline 260-269 syntaxin 8 Homo sapiens 32-36 22386978-0 2012 C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors. quinoline 31-40 complement C2 Homo sapiens 22-25 22386978-0 2012 C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors. quinoline 31-40 phosphodiesterase 4A Homo sapiens 132-136 22248236-1 2012 Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. quinoline 57-66 AKT serine/threonine kinase 1 Homo sapiens 100-103 22277589-0 2012 Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation. quinoline 0-9 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 96-102 22206487-0 2012 Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2. quinoline 55-64 N-ribosyldihydronicotinamide:quinone reductase 2 Homo sapiens 124-143 22227212-1 2012 A series of pyrazoloquinolines, possessing (hetero)arylhydroxymethyl substituents at the quinoline C-4 position were evaluated as PDE10A inhibitors. quinoline 20-29 phosphodiesterase 10A Homo sapiens 130-136 22148183-2 2012 In the presence of a highly efficient combination encompassing (PPh)(3)AuCl and AgOTf, the reactions between 2-aminocarbonyls and an array of internal alkynes proceeded smoothly to afford quinoline derivatives in good to excellent yields (up to 93%). quinoline 188-197 enolase 1 Homo sapiens 64-67 22455594-0 2012 The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity. quinoline 4-13 AKT serine/threonine kinase 1 Homo sapiens 52-55 23036152-2 2012 By studying the structure-activity relationship (SAR) of salubrinal, it was found that modification of the quinoline ring terminus and thiourea unit could confer the compound PP1-24 with markedly enhanced cardioprotective activity (EC50 <= 0.3 muM) that is 50-fold more potent than salubrinal. quinoline 107-116 inorganic pyrophosphatase 1 Homo sapiens 175-178 22455594-0 2012 The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity. quinoline 4-13 mechanistic target of rapamycin kinase Homo sapiens 56-60 22232002-0 2012 Molecules of the quinoline family block tau self-aggregation: implications toward a therapeutic approach for Alzheimer"s disease. quinoline 17-26 microtubule associated protein tau Homo sapiens 40-43 22949848-0 2012 2,3-dihydro-1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase inhibitors-synthesis, radiolabeling and biodistribution. quinoline 28-37 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-73 22232002-7 2012 In vitro studies indicated a significantly lower inhibitory effect of amyloid-beta42 on the aggregation, suggesting that tau aggregates are specific targets for quinoline interactions. quinoline 161-170 microtubule associated protein tau Homo sapiens 121-124 21807395-1 2011 Di- and trimeric quinoline derivatives have been recently described as potential modulators of Bcl-2 family protein interactions. quinoline 17-26 BCL2 apoptosis regulator Homo sapiens 95-100 23077529-4 2012 We have designed and synthesized a series of organometallic tricarbonyl-rhenium complexes conjugated to a GPER-selective small molecule derived from tetrahydro-3H-cyclopenta[c]quinoline. quinoline 176-185 G protein-coupled estrogen receptor 1 Homo sapiens 106-110 21920748-1 2011 The quinoline domain of OSI-930, a dual inhibitor of receptor tyrosine kinases (RTKs) c-Kit and KDR, was modified in an effort to further understand the SAR of OSI-930, and the binding site characteristics of c-Kit and KDR. quinoline 4-13 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 86-91 21741847-0 2011 Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. quinoline 56-65 dipeptidylpeptidase 4 Rattus norvegicus 72-95 21741847-2 2011 In our studies involving non-covalent DPP-4 inhibitors, a novel series of quinoline-based inhibitors were designed based on the co-crystal structure of isoquinolone 2 in complex with DPP-4 to target the side chain of Lys554. quinoline 74-83 dipeptidylpeptidase 4 Rattus norvegicus 38-43 21741847-2 2011 In our studies involving non-covalent DPP-4 inhibitors, a novel series of quinoline-based inhibitors were designed based on the co-crystal structure of isoquinolone 2 in complex with DPP-4 to target the side chain of Lys554. quinoline 74-83 dipeptidylpeptidase 4 Rattus norvegicus 183-188 21886897-1 2011 Considering the significance of progesterone receptor (PR) modulators, the present study is explored to envisage the biophoric signals for binding to selective PR subtype-A using ligand-based quantitative structure activity relationship (QSAR) and pharmacophore space modeling studies on nonsteroidal substituted quinoline and cyclocymopol monomethyl ether derivatives. quinoline 313-322 progesterone receptor Homo sapiens 32-53 21648459-2 2011 By significantly decreasing the rotation rate of the quinoline-carbinol bond, the relatively bulky CF(3) group enables the NMR signals of the syn and anti conformers to be differentiated at room temperature. quinoline 53-62 synemin Homo sapiens 142-145 21612232-0 2011 Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. quinoline 150-159 mechanistic target of rapamycin kinase Homo sapiens 34-63 21612232-0 2011 Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. quinoline 150-159 mechanistic target of rapamycin kinase Homo sapiens 65-69 21754086-2 2011 The configuration about each of the ethyl-ene bonds [1.342 (2) and 1.338 (2) A] is E. The three-dimensional crystal structure is stabilized by a combination of C-H O, C-H N, C-H pi inter-actions and pi-pi contacts between the independent mol-ecules [Cg(C(6) of quinoline) Cg(C(6) of quinoline) = 3.6719 (11) A]. quinoline 261-270 chimerin 1 Homo sapiens 160-177 21501579-2 2011 Diethyl and dibutyl [alpha-anilino-(quinolin-2-ylmethyl)]phosphonates (L1, L2) act as N,N-chelate ligands through the quinoline and aniline nitrogens giving complexes cis-[Pd(L1/L2)X(2)] (X Cl, Br) (1-4). quinoline 118-127 CD274 molecule Homo sapiens 172-177 21754086-2 2011 The configuration about each of the ethyl-ene bonds [1.342 (2) and 1.338 (2) A] is E. The three-dimensional crystal structure is stabilized by a combination of C-H O, C-H N, C-H pi inter-actions and pi-pi contacts between the independent mol-ecules [Cg(C(6) of quinoline) Cg(C(6) of quinoline) = 3.6719 (11) A]. quinoline 283-292 chimerin 1 Homo sapiens 160-177 21251824-2 2011 This Letter describes the medicinal chemistry effort towards a series of 8-amino-imidazo[1,5-a]pyrazine derived inhibitors of IGF-1R which features a substituted quinoline moiety at the C1 position and a cyclohexyl linking moiety at the C3 position. quinoline 162-171 insulin-like growth factor I receptor Mus musculus 126-132 21421318-1 2011 The quinoline nucleus of the previously described 4-phenylquinoline-3-carboxamides NK(1) receptor ligands 7 has been transformed into either substituted or azole-(i.e., triazole or tetrazole) fused pyridine moieties of compounds 9 and 10, respectively, in order to obtain NK(1) receptor ligands showing lower molecular weight or higher hydrophilicity. quinoline 4-13 tachykinin receptor 1 Homo sapiens 83-97 21421318-1 2011 The quinoline nucleus of the previously described 4-phenylquinoline-3-carboxamides NK(1) receptor ligands 7 has been transformed into either substituted or azole-(i.e., triazole or tetrazole) fused pyridine moieties of compounds 9 and 10, respectively, in order to obtain NK(1) receptor ligands showing lower molecular weight or higher hydrophilicity. quinoline 4-13 tachykinin receptor 1 Homo sapiens 272-286 21256005-2 2011 The quinoline 1c was an equipotent FXR agonist with improved drug developability parameters relative to 1b. quinoline 4-13 nuclear receptor subfamily 1, group H, member 4 Mus musculus 35-38 21277656-1 2011 A QSAR (quantitative structure-activity relationship) analysis of the binding affinities for a series of 43 quinoline derivatives active against the alpha2C adrenergic receptor was performed. quinoline 108-117 adrenoceptor alpha 2C Homo sapiens 149-176 20961670-4 2010 SAR showed that the compounds having quinoline ring and hydrazone linkage with free N-H group are responsible for higher antiamoebic activity. quinoline 37-46 sarcosine dehydrogenase Homo sapiens 0-3 21215643-0 2011 Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists. quinoline 32-41 cannabinoid receptor 2 Homo sapiens 100-103 21215643-1 2011 Quinoline, isoquinoline, quinoxaline, and quinazoline derivatives were synthesized using microwave-assisted synthesis and their CB1/CB2 receptor activities were determined using the [35S]GTPgammaS binding assay. quinoline 0-9 cannabinoid receptor 1 Homo sapiens 128-131 21215643-1 2011 Quinoline, isoquinoline, quinoxaline, and quinazoline derivatives were synthesized using microwave-assisted synthesis and their CB1/CB2 receptor activities were determined using the [35S]GTPgammaS binding assay. quinoline 0-9 cannabinoid receptor 2 Homo sapiens 132-135 21215643-2 2011 Most of the prepared quinoline, isoquinoline, and quinoxalinyl phenyl amines showed low-potency partial CB2 receptor agonists activity. quinoline 21-30 cannabinoid receptor 2 Homo sapiens 104-107 20585026-3 2010 We hypothesize that the antimalarial quinoline chloroquine exerts potent antiarrhythmic effects by interacting with the cytoplasmic domains of Kir2.1 (I(K1)), Kir3.1 (I(KACh)), or Kir6.2 (I(KATP)) and reducing inward rectifier potassium currents. quinoline 37-46 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 143-149 20850973-1 2010 A previously utilized quinoline-for-N-phenylamide replacement strategy was employed against a central amide in a novel class of CGRP receptor antagonists. quinoline 22-31 calcitonin related polypeptide alpha Homo sapiens 128-132 20850973-3 2010 Subsequently, specific quinoline and naphthyridine compounds were prepared which supported these structural predictions by displaying CGRP binding affinities in the 0.037-0.15 nM range. quinoline 23-32 calcitonin related polypeptide alpha Homo sapiens 134-138 20585026-3 2010 We hypothesize that the antimalarial quinoline chloroquine exerts potent antiarrhythmic effects by interacting with the cytoplasmic domains of Kir2.1 (I(K1)), Kir3.1 (I(KACh)), or Kir6.2 (I(KATP)) and reducing inward rectifier potassium currents. quinoline 37-46 potassium inwardly rectifying channel subfamily J member 3 Homo sapiens 159-165 20585026-3 2010 We hypothesize that the antimalarial quinoline chloroquine exerts potent antiarrhythmic effects by interacting with the cytoplasmic domains of Kir2.1 (I(K1)), Kir3.1 (I(KACh)), or Kir6.2 (I(KATP)) and reducing inward rectifier potassium currents. quinoline 37-46 potassium inwardly rectifying channel subfamily J member 11 Homo sapiens 180-186 21588864-1 2010 In the title complex, [Ca(C(10)H(6)NO(2))(2)(H(2)O)(2)](n), the Ca(II) ion is eight-coordinated by six carboxyl-ate O atoms from four separate quinoline-3-carboxyl-ate ligands, two of which are bidentate chelate and two bridging, and two water mol-ecules in a distorted square-anti-prismatic geometry. quinoline 143-152 carbonic anhydrase 2 Homo sapiens 64-70 20860370-2 2010 Starting from quinoline 1, which was identified in a biochemical mTOR assay, we developed a tricyclic benzonaphthyridinone inhibitor 37 (Torin1), which inhibited phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. quinoline 14-23 mechanistic target of rapamycin kinase Homo sapiens 65-69 20860370-2 2010 Starting from quinoline 1, which was identified in a biochemical mTOR assay, we developed a tricyclic benzonaphthyridinone inhibitor 37 (Torin1), which inhibited phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. quinoline 14-23 CREB regulated transcription coactivator 1 Mus musculus 181-187 20860370-2 2010 Starting from quinoline 1, which was identified in a biochemical mTOR assay, we developed a tricyclic benzonaphthyridinone inhibitor 37 (Torin1), which inhibited phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. quinoline 14-23 CREB regulated transcription coactivator 2 Mus musculus 192-198 20727743-1 2010 The dissociated glucocorticoid receptor (GR) agonist ZK 216348 is rendered GR-selective over other nuclear hormone receptors through replacing the methylbenzoxazine with a quinoline moiety. quinoline 172-181 nuclear receptor subfamily 3 group C member 1 Homo sapiens 16-39 20727743-1 2010 The dissociated glucocorticoid receptor (GR) agonist ZK 216348 is rendered GR-selective over other nuclear hormone receptors through replacing the methylbenzoxazine with a quinoline moiety. quinoline 172-181 nuclear receptor subfamily 3 group C member 1 Homo sapiens 41-43 20727743-1 2010 The dissociated glucocorticoid receptor (GR) agonist ZK 216348 is rendered GR-selective over other nuclear hormone receptors through replacing the methylbenzoxazine with a quinoline moiety. quinoline 172-181 nuclear receptor subfamily 3 group C member 1 Homo sapiens 75-77 20512187-5 2010 In addition the complexes based upon L1-3 also possessed ligand-centred fluorescence, originating from either the quinoline or 8-hydroxyquinoline units of the axial ligands. quinoline 114-123 immunoglobulin kappa variable 2-4 (pseudogene) Homo sapiens 37-41 20735208-3 2010 This is the first study to apply ring-closing metathesis toward synthesis of the quinoline nucleus for this 4-anilinoquinoline EGFR inhibitor. quinoline 81-90 epidermal growth factor receptor Mus musculus 127-131 20518620-1 2010 Structural modifications around 8-HETE (8-hydroxyeicosatetraenoic acid), a natural agonist of the PPAR (peroxisome proliferator-activated receptor) nuclear receptors have led previously to the identification of a promising analog, the quinoline S 70655. quinoline 235-244 peroxisome proliferator activated receptor alpha Homo sapiens 98-102 20518620-1 2010 Structural modifications around 8-HETE (8-hydroxyeicosatetraenoic acid), a natural agonist of the PPAR (peroxisome proliferator-activated receptor) nuclear receptors have led previously to the identification of a promising analog, the quinoline S 70655. quinoline 235-244 peroxisome proliferator activated receptor alpha Homo sapiens 104-146 20847170-14 2010 CONCLUSION: Experiments in rats and PDE10A knock-out mice indicate that (18)F-JNJ41510417 binds specifically and reversibly to PDE10A in the striatum, suggesting that this new fluorinated quinoline derivative is a promising candidate for in vivo imaging of PDE10A using PET. quinoline 188-197 phosphodiesterase 10A Mus musculus 127-133 20847170-14 2010 CONCLUSION: Experiments in rats and PDE10A knock-out mice indicate that (18)F-JNJ41510417 binds specifically and reversibly to PDE10A in the striatum, suggesting that this new fluorinated quinoline derivative is a promising candidate for in vivo imaging of PDE10A using PET. quinoline 188-197 phosphodiesterase 10A Mus musculus 127-133 20600334-0 2010 Quinoline-based compounds as modulators of HIV transcription through NF-kappaB and Sp1 inhibition. quinoline 0-9 nuclear factor kappa B subunit 1 Homo sapiens 69-78 20690626-1 2010 We have presented new amino-NHC Ni-Al complex mediated para C-H bond activation for pyridine and quinolin, and isolated for the first time the intermediate structure of a bimetallic eta(2),eta(1)-pyridine nickel aluminum complex prior to its C-H activation, which serves as key evidence for bimetallic catalysis. quinoline 97-105 DNA polymerase iota Homo sapiens 182-187 20061161-5 2010 The structure activity data acquired indicate that the size and nature of the C-4 quinoline substituent are important for COX-2 inhibitory activity. quinoline 82-91 complement C4A (Rodgers blood group) Homo sapiens 78-81 20432490-5 2010 Based on the results of transferred NOE experiments in the presence of tubulin, the isomeric C15 quinoline-based Epo B analogues 4 and 5 show very similar orientations of the side chain, irrespective of the position of the nitrogen atom in the quinoline ring. quinoline 97-106 placenta associated 8 Homo sapiens 93-96 20432490-5 2010 Based on the results of transferred NOE experiments in the presence of tubulin, the isomeric C15 quinoline-based Epo B analogues 4 and 5 show very similar orientations of the side chain, irrespective of the position of the nitrogen atom in the quinoline ring. quinoline 244-253 placenta associated 8 Homo sapiens 93-96 20187041-1 2010 A pair of molecular tweezers (syn-4) that consists of quinoline and pyrazine units fused to a bicyclic framework is presented. quinoline 54-63 syntrophin gamma 1 Homo sapiens 30-35 20308316-4 2010 We show that the quinoline derivative chloroquine activates the p53 pathway and suppresses growth of glioma cells in vitro and in vivo in an orthotopic (U87MG) human glioblastoma mouse model. quinoline 17-26 tumor protein p53 Homo sapiens 64-67 20189815-0 2010 Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. quinoline 66-75 cannabinoid receptor 2 Homo sapiens 138-141 20093027-1 2010 A novel quinoline derivative that selectively inhibits c-Met kinase was identified. quinoline 8-17 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 55-60 20061161-2 2010 In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-4 quinoline ring. quinoline 109-118 mitochondrially encoded cytochrome c oxidase I Homo sapiens 9-14 20061161-2 2010 In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-4 quinoline ring. quinoline 109-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 20061161-2 2010 In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-4 quinoline ring. quinoline 109-118 complement C4A (Rodgers blood group) Homo sapiens 105-108 20382541-2 2010 We have discovered that the rigid diaryl alkyne template, derived from the potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), can serve to guide the design of novel quinoline analogues and pharmacophore optimization has resulted in potent mGluR5 noncompetitive antagonists (EC(50) range 60-100 nM) in the quinoline series. quinoline 211-220 glutamate receptor, ionotropic, kainate 1 Mus musculus 111-117 20382541-2 2010 We have discovered that the rigid diaryl alkyne template, derived from the potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), can serve to guide the design of novel quinoline analogues and pharmacophore optimization has resulted in potent mGluR5 noncompetitive antagonists (EC(50) range 60-100 nM) in the quinoline series. quinoline 211-220 glutamate receptor, ionotropic, kainate 1 Mus musculus 285-291 20382541-2 2010 We have discovered that the rigid diaryl alkyne template, derived from the potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), can serve to guide the design of novel quinoline analogues and pharmacophore optimization has resulted in potent mGluR5 noncompetitive antagonists (EC(50) range 60-100 nM) in the quinoline series. quinoline 351-360 glutamate receptor, ionotropic, kainate 1 Mus musculus 111-117 20382541-2 2010 We have discovered that the rigid diaryl alkyne template, derived from the potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), can serve to guide the design of novel quinoline analogues and pharmacophore optimization has resulted in potent mGluR5 noncompetitive antagonists (EC(50) range 60-100 nM) in the quinoline series. quinoline 351-360 glutamate receptor, ionotropic, kainate 1 Mus musculus 285-291 20299218-1 2010 A novel series of potent CGRP receptor antagonists containing a central quinoline ring constraint was identified. quinoline 72-81 calcitonin related polypeptide alpha Homo sapiens 25-29 20299218-2 2010 The combination of the quinoline constraint with a tricyclic benzimidazolinone left hand fragment produced an analog with picomolar potency (14, CGRP K(i)=23 pM). quinoline 23-32 calcitonin related polypeptide alpha Homo sapiens 145-149 20436212-8 2010 The quinoline agent mefloquine inhibited WT KCNQ1+KCNE1 with an IC(50) of 3.4 muM compared to 3.3 muM for V307L KCNQ1+KCNE1 (P >0.05). quinoline 4-13 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 44-49 20436212-8 2010 The quinoline agent mefloquine inhibited WT KCNQ1+KCNE1 with an IC(50) of 3.4 muM compared to 3.3 muM for V307L KCNQ1+KCNE1 (P >0.05). quinoline 4-13 potassium voltage-gated channel subfamily E regulatory subunit 1 Homo sapiens 50-55 20436212-8 2010 The quinoline agent mefloquine inhibited WT KCNQ1+KCNE1 with an IC(50) of 3.4 muM compared to 3.3 muM for V307L KCNQ1+KCNE1 (P >0.05). quinoline 4-13 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 112-117 20436212-8 2010 The quinoline agent mefloquine inhibited WT KCNQ1+KCNE1 with an IC(50) of 3.4 muM compared to 3.3 muM for V307L KCNQ1+KCNE1 (P >0.05). quinoline 4-13 potassium voltage-gated channel subfamily E regulatory subunit 1 Homo sapiens 118-123 20061161-5 2010 The structure activity data acquired indicate that the size and nature of the C-4 quinoline substituent are important for COX-2 inhibitory activity. quinoline 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 20039701-3 2010 By potentiometric pH, (1)H NMR, and UV-vis spectroscopic titrations, the deprotonation constants pK(a1)-pK(a6) of H(5)L(6) were determined to be <2, <2, <2, 2.5 +/- 0.1 (for the 8-OH group of the quinoline moiety), 9.7 +/- 0.1, and 10.8 +/- 0.1 at 25 degrees C with I = 0.1 (NaNO(3)). quinoline 205-214 transmembrane 4 L six family member 1 Homo sapiens 118-122 20000450-15 2010 Significant spin population on the quinoline also contributes to a lowering of the D value, as observed when (3(**))(2+) is compared to (1(**))(2+) (and also when (4(**))(2+) is compared to (2(**))(2+)). quinoline 35-44 spindlin 1 Homo sapiens 12-16 19962892-2 2010 The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRbeta over LXRalpha (LXRbeta IC(50)=16nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the LXRalpha Gal4 functional assay, and low blood-brain barrier penetration in rat. quinoline 9-18 nuclear receptor subfamily 1, group H, member 3 Rattus norvegicus 108-116 19928858-5 2010 Additionally, we present protein X-ray crystallography studies to examine the binding modes of potent quinoline-based DFG-out binders in p38alpha. quinoline 102-111 mitogen-activated protein kinase 14 Homo sapiens 137-145 19962892-2 2010 The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRbeta over LXRalpha (LXRbeta IC(50)=16nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the LXRalpha Gal4 functional assay, and low blood-brain barrier penetration in rat. quinoline 9-18 ATP binding cassette subfamily A member 1 Rattus norvegicus 167-172 19962892-2 2010 The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRbeta over LXRalpha (LXRbeta IC(50)=16nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the LXRalpha Gal4 functional assay, and low blood-brain barrier penetration in rat. quinoline 9-18 nuclear receptor subfamily 1, group H, member 3 Rattus norvegicus 248-256 19843078-0 2009 Combined 3D-QSAR modeling and molecular docking study on quinoline derivatives as inhibitors of P-selectin. quinoline 57-66 selectin P Homo sapiens 96-106 20391191-1 2010 We report the synthesis of new photonuclease consisting of two Co(II)/Cu(II) complexes of macrocyclic fused quinoline. quinoline 108-117 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-69 19673889-4 2009 Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both. quinoline 38-47 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 19673889-4 2009 Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both. quinoline 38-47 phosphoglycolate phosphatase Homo sapiens 112-116 19673889-4 2009 Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both. quinoline 38-47 ATP binding cassette subfamily C member 1 Homo sapiens 118-123 19572644-8 2009 Additionally, we used protein X-ray crystallography together with our assay to examine the binding and dissociation kinetics to characterize potent quinazoline- and quinoline-based type II inhibitors, which also utilize this binding pocket in p38alpha. quinoline 165-174 mitogen-activated protein kinase 14 Homo sapiens 243-251 19497742-1 2009 MCH1R inhibitors with the quinoline moiety having the aromatic amine and aliphatic amine chain were selected, and then the effect of substituents of the quinoline ring on the ionic interaction were studied by calculating pK(a) values for these amines at the B3LYP/6-311++G(d,p)//B3LYP/6-31+G(d) level in the gas phase and in water. quinoline 26-35 melanin concentrating hormone receptor 1 Homo sapiens 0-5 19497742-1 2009 MCH1R inhibitors with the quinoline moiety having the aromatic amine and aliphatic amine chain were selected, and then the effect of substituents of the quinoline ring on the ionic interaction were studied by calculating pK(a) values for these amines at the B3LYP/6-311++G(d,p)//B3LYP/6-31+G(d) level in the gas phase and in water. quinoline 153-162 melanin concentrating hormone receptor 1 Homo sapiens 0-5 19524437-5 2009 Encouraged by the promising profile of the naphthalene series, we used our deeper understanding of the H(3)R pharmacophore model to lead us towards the quinoline series. quinoline 152-161 histamine receptor H3 Homo sapiens 103-108 19552431-3 2009 First, known quinoline-based B(2) receptor antagonists were stripped down to their shared core motif 53, which turned out to be the minimum pharmacophore. quinoline 13-22 bradykinin receptor B2 Homo sapiens 29-42 19292551-3 2009 Values are calculated for the adsorption energies of butadiene, thiophene, benzothiophene, pyridine, quinoline, benzene, and naphthalene on the basal plane of MoS(2), showing good agreement with available experimental data, and the equilibrium geometry is found as flat at a separation of about 3.5 A for all studied molecules. quinoline 101-110 MOS proto-oncogene, serine/threonine kinase Homo sapiens 159-162 19518068-2 2009 Reaction of 1,1-diethyl 2-tert-butyl ethenetricarboxylate 1b with 2-(trimethylsilylethynyl)aniline substrates in the presence of Zn(OTf)(2) gave bridged quinoline derivatives in 43-85% yield. quinoline 153-162 POU class 2 homeobox 2 Homo sapiens 129-138 19560931-2 2009 In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-7 and C-8 quinoline ring. quinoline 117-126 mitochondrially encoded cytochrome c oxidase I Homo sapiens 9-14 19560931-2 2009 In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-7 and C-8 quinoline ring. quinoline 117-126 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 19560931-2 2009 In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-7 and C-8 quinoline ring. quinoline 117-126 homeobox C8 Homo sapiens 113-116 19560931-5 2009 The structure activity data acquired indicate that the presence of lipophilic substituents on the C-7 and C-8 quinoline ring is important for COX-2 inhibitory activity. quinoline 110-119 homeobox C8 Homo sapiens 106-109 19560931-5 2009 The structure activity data acquired indicate that the presence of lipophilic substituents on the C-7 and C-8 quinoline ring is important for COX-2 inhibitory activity. quinoline 110-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 19417133-0 2009 A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. quinoline 15-24 DNA methyltransferase 1 Rattus norvegicus 105-128 19417133-4 2009 Here, we report that a quinoline-based compound, designated SGI-1027, inhibits the activity of DNMT1, DNMT3A, and DNMT3B as well M. SssI with comparable IC(50) (6-13 micromol/L) by competing with S-adenosylmethionine in the methylation reaction. quinoline 23-32 chromogranin B Rattus norvegicus 60-63 19417133-4 2009 Here, we report that a quinoline-based compound, designated SGI-1027, inhibits the activity of DNMT1, DNMT3A, and DNMT3B as well M. SssI with comparable IC(50) (6-13 micromol/L) by competing with S-adenosylmethionine in the methylation reaction. quinoline 23-32 DNA methyltransferase 1 Rattus norvegicus 95-100 19417133-4 2009 Here, we report that a quinoline-based compound, designated SGI-1027, inhibits the activity of DNMT1, DNMT3A, and DNMT3B as well M. SssI with comparable IC(50) (6-13 micromol/L) by competing with S-adenosylmethionine in the methylation reaction. quinoline 23-32 DNA methyltransferase 3 alpha Rattus norvegicus 102-108 19417133-4 2009 Here, we report that a quinoline-based compound, designated SGI-1027, inhibits the activity of DNMT1, DNMT3A, and DNMT3B as well M. SssI with comparable IC(50) (6-13 micromol/L) by competing with S-adenosylmethionine in the methylation reaction. quinoline 23-32 DNA methyltransferase 3 beta Rattus norvegicus 114-120 20808725-1 2009 Syntheses of two new cobaltacarborane-phthalocyanine conjugates, one anionic (Pc 6) and one zwitterionic (Pc 7), were accomplished via cyclotetramerization of the corresponding cobaltacarborane-substituted phthalonitriles (4 or 5) with excess phthalonitrile in quinoline. quinoline 261-270 proprotein convertase subtilisin/kexin type 5 Homo sapiens 78-82 19217787-0 2009 Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors. quinoline 54-63 RNA binding motif protein 8A Homo sapiens 89-92 19217787-1 2009 Thirty-two quinoline derivatives were designed and synthesized as HIV-1 Tat-TAR interaction inhibitors. quinoline 11-20 RNA binding motif protein 8A Homo sapiens 76-79 19166365-4 2009 The results of density functional theory (DFT) calculations indicate that these results can be rationalized by invoking the existence of an equilibrium of hydrolysis of the Cu-N bond with the amino group supporting the quinoline ring so that CuL1(2+) would be actually a mixture of tbp [CuL1(H(2)O)](2+) and sp [CuL1(H(2)O)(2)](2+). quinoline 219-228 cullin 1 Homo sapiens 242-246 19144517-1 2009 We identified a series of 4-hydroxyquinolines bearing a C1 to C15 alkyl chain at the C2 position and a carbethoxy/carboxy group at the C3 position of the quinoline nucleus (MC compounds), endowed with selective inhibitory activity against the p300/CBP HAT enzymes. quinoline 35-44 E1A binding protein p300 Homo sapiens 243-247 19144517-1 2009 We identified a series of 4-hydroxyquinolines bearing a C1 to C15 alkyl chain at the C2 position and a carbethoxy/carboxy group at the C3 position of the quinoline nucleus (MC compounds), endowed with selective inhibitory activity against the p300/CBP HAT enzymes. quinoline 35-44 CREB binding protein Homo sapiens 248-251 19166365-4 2009 The results of density functional theory (DFT) calculations indicate that these results can be rationalized by invoking the existence of an equilibrium of hydrolysis of the Cu-N bond with the amino group supporting the quinoline ring so that CuL1(2+) would be actually a mixture of tbp [CuL1(H(2)O)](2+) and sp [CuL1(H(2)O)(2)](2+). quinoline 219-228 cullin 1 Homo sapiens 287-291 19166365-4 2009 The results of density functional theory (DFT) calculations indicate that these results can be rationalized by invoking the existence of an equilibrium of hydrolysis of the Cu-N bond with the amino group supporting the quinoline ring so that CuL1(2+) would be actually a mixture of tbp [CuL1(H(2)O)](2+) and sp [CuL1(H(2)O)(2)](2+). quinoline 219-228 cullin 1 Homo sapiens 287-291 19117759-0 2009 New quinoline NK3 receptor antagonists with CNS activity. quinoline 4-13 tachykinin receptor 3 Homo sapiens 14-26 19117759-1 2009 Lead optimisation starting from the previously reported selective quinoline NK(3) receptor antagonists talnetant 2 (SB-223412) and 3 (SB-222200) led to the identification of 3-aminoquinoline NK(3) antagonist 10 (GSK172981) with excellent CNS penetration. quinoline 66-75 tachykinin receptor 3 Homo sapiens 76-90 19160437-8 2009 The bis-chelate triflate complexes C9 and C10, supported by quinoline-guanidine ligands L3 and L4, exhibit by far the highest reactivity. quinoline 60-69 homeobox C10 Homo sapiens 42-45 18993099-2 2008 Ligand-based model, 3D-pharmacophore was generated using 27 quinoline salicylic acid compounds and is used to retrieve the actives of P-selectin. quinoline 60-69 selectin P Homo sapiens 134-144 19026174-7 2008 CONCLUSION: This study was the first to identify new structural types of antiproliferative agents against the EGFR-overexpressing tumor cell lines by the incorporation of the nitro group at the 3-position of the quinoline core structure, providing promising new templates for the further development of anticancer agents. quinoline 212-221 epidermal growth factor receptor Homo sapiens 110-114 18554914-1 2008 The substituent in position 2 of the quinoline nucleus of NK(1) receptor ligands 5 has been constrained into different five-membered heterocyclic moieties in order to obtain information on the binding site pocket interacting with this apparently critical portion of ligands 5. quinoline 37-46 tachykinin receptor 1 Homo sapiens 58-72 18773515-2 2008 The product was characterized by NMR, IR, differential thermal thermogravimetric analysis (DT-TGA), spectrofluorimetry, and elemental analysis, indicating the formation of inclusion complex in which the quinoline rings of the guest were encapsulated within the beta-CD cavities. quinoline 203-212 T-box transcription factor 1 Homo sapiens 94-97 18645022-6 2008 Quinoline derivative triggered transient, p53-independent G(2)-M arrest in mutant p53 cells (SW620) and succeeding mitotic transition, whereby these cells underwent cell death probably due to aberrant mitosis (mitotic catastrophe). quinoline 0-9 tumor protein p53 Homo sapiens 42-45 18645022-6 2008 Quinoline derivative triggered transient, p53-independent G(2)-M arrest in mutant p53 cells (SW620) and succeeding mitotic transition, whereby these cells underwent cell death probably due to aberrant mitosis (mitotic catastrophe). quinoline 0-9 tumor protein p53 Homo sapiens 82-85 18510350-1 2008 Potential receptor imaging agents based on Tc-99m for the in vivo visualization of the peripheral benzodiazepine receptor (PBR) have been designed on the basis of the information provided by the previously published structure-affinity relationship studies, which suggested the existence of tolerance to voluminous substituents in the receptor area interacting with 3-position of the quinoline nucleus of 2-quinolinecarboxamides 5. quinoline 383-392 translocator protein Homo sapiens 87-121 18510350-1 2008 Potential receptor imaging agents based on Tc-99m for the in vivo visualization of the peripheral benzodiazepine receptor (PBR) have been designed on the basis of the information provided by the previously published structure-affinity relationship studies, which suggested the existence of tolerance to voluminous substituents in the receptor area interacting with 3-position of the quinoline nucleus of 2-quinolinecarboxamides 5. quinoline 383-392 translocator protein Homo sapiens 123-126 18477508-1 2008 A series of quinoline/naphthalene-difluoromethylphosphonates were prepared and were found to be potent PTP1B inhibitors. quinoline 12-22 protein tyrosine phosphatase non-receptor type 1 Homo sapiens 103-108 17964000-0 2008 Structure activity relationships of quinoline-containing c-Met inhibitors. quinoline 36-45 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 57-62 17964000-1 2008 A series of quinoline-containing c-Met inhibitors were prepared and studied. quinoline 12-21 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 33-38 17828732-0 2008 Improved intestinal membrane permeability of hexose-quinoline derivatives via the hexose transporter, SGLT1. quinoline 52-61 solute carrier family 5 (sodium/glucose cotransporter), member 1, gene 2 L homeolog Xenopus laevis 102-107 17828732-5 2008 Three hexose-quinoline derivatives were synthesized and their interactions with SGLT1 were evaluated. quinoline 13-22 solute carrier family 5 (sodium/glucose cotransporter), member 1, gene 2 L homeolog Xenopus laevis 80-85 17828732-6 2008 Among the three derivatives, the glucose-quinoline molecule exhibited an inhibitory effect on D-glucose uptake by both rat intestinal brush-border membrane vesicles (BBMVs) and Xenopus oocytes expressing SGLT1. quinoline 41-50 solute carrier family 5 (sodium/glucose cotransporter), member 1, gene 2 L homeolog Xenopus laevis 204-209 17980608-1 2008 With the aim of searching of novel amyloid-specific fluorescent probes the ability of series of mono- and trimethine cyanines based on benzothiazole, pyridine and quinoline heterocycle end groups to recognize fibrillar formations of alpha-synuclein (ASN) was studied. quinoline 163-172 synuclein alpha Homo sapiens 233-248 17828732-7 2008 In addition, significant uptake of the glucose-quinoline derivative by Xenopus oocytes expressing SGLT1 was observed by both an electrophysiological assay and direct measurement of the uptake of the compound, while the galactose-quinoline derivative did not show significant uptake via SGLT1. quinoline 47-56 solute carrier family 5 (sodium/glucose cotransporter), member 1, gene 2 L homeolog Xenopus laevis 98-103 17828732-7 2008 In addition, significant uptake of the glucose-quinoline derivative by Xenopus oocytes expressing SGLT1 was observed by both an electrophysiological assay and direct measurement of the uptake of the compound, while the galactose-quinoline derivative did not show significant uptake via SGLT1. quinoline 47-56 solute carrier family 5 (sodium/glucose cotransporter), member 1, gene 2 L homeolog Xenopus laevis 286-291 18324762-0 2008 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. quinoline 80-89 RNA, U1 small nuclear 1 Homo sapiens 151-206 18314943-1 2008 In our continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, we have discovered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability. quinoline 50-59 sarcosine dehydrogenase Homo sapiens 39-42 17980608-1 2008 With the aim of searching of novel amyloid-specific fluorescent probes the ability of series of mono- and trimethine cyanines based on benzothiazole, pyridine and quinoline heterocycle end groups to recognize fibrillar formations of alpha-synuclein (ASN) was studied. quinoline 163-172 synuclein alpha Homo sapiens 250-253 18005334-0 2007 Comparative molecular field analysis of quinoline derivatives as selective and noncompetitive mGluR1 antagonists. quinoline 40-49 glutamate metabotropic receptor 1 Homo sapiens 94-100 18023179-2 2008 With the aid of molecular modeling, it was found that 2,3-diMe-Ph, 2,5-diMe-Ph, and naphthalene substituted quinoline acetic acids (such as quinoline 33, 37, and 38) showed selectivity for LXRbeta over LXRalpha in binding assays. quinoline 108-117 nuclear receptor subfamily 1 group H member 2 Homo sapiens 189-196 18023179-2 2008 With the aid of molecular modeling, it was found that 2,3-diMe-Ph, 2,5-diMe-Ph, and naphthalene substituted quinoline acetic acids (such as quinoline 33, 37, and 38) showed selectivity for LXRbeta over LXRalpha in binding assays. quinoline 108-117 nuclear receptor subfamily 1 group H member 3 Homo sapiens 202-210 18005334-1 2007 A 3D- QSAR model os Comparative Molecular Field Analysib (CoMFA) of 45 quinoline derivatives as metaborropic glutamate receptor subtype 1 (mGluR1) inhibitors wew investigated. quinoline 71-80 glutamate metabotropic receptor 1 Homo sapiens 96-137 18005334-1 2007 A 3D- QSAR model os Comparative Molecular Field Analysib (CoMFA) of 45 quinoline derivatives as metaborropic glutamate receptor subtype 1 (mGluR1) inhibitors wew investigated. quinoline 71-80 glutamate metabotropic receptor 1 Homo sapiens 139-145 18045063-10 2007 It has been observed that aniline group at C-4, aminoacrylamide substituents at C-6, cyano group at C-3 and alkoxy groups at C-7 in the quinoline ring play an important role for optimal activity. quinoline 136-145 complement C4A (Rodgers blood group) Homo sapiens 43-46 17942307-0 2007 New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. quinoline 26-35 cannabinoid receptor 2 Homo sapiens 51-54 18045063-10 2007 It has been observed that aniline group at C-4, aminoacrylamide substituents at C-6, cyano group at C-3 and alkoxy groups at C-7 in the quinoline ring play an important role for optimal activity. quinoline 136-145 complement C6 Homo sapiens 80-83 18045063-10 2007 It has been observed that aniline group at C-4, aminoacrylamide substituents at C-6, cyano group at C-3 and alkoxy groups at C-7 in the quinoline ring play an important role for optimal activity. quinoline 136-145 complement C3 Homo sapiens 100-103 18045063-10 2007 It has been observed that aniline group at C-4, aminoacrylamide substituents at C-6, cyano group at C-3 and alkoxy groups at C-7 in the quinoline ring play an important role for optimal activity. quinoline 136-145 complement C7 Homo sapiens 125-128 17610302-0 2007 Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists. quinoline 0-9 peroxisome proliferator activated receptor alpha Homo sapiens 54-64 17918921-0 2007 Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists. quinoline 44-53 histamine receptor H3 Homo sapiens 65-86 17681953-10 2007 Conversely, cells treated with the quinoline-Val Asp-2,6-difluorophenoxymethylketone caspase inhibitor proliferated more slowly and exhibited delayed S phase entry following exit from quiescence. quinoline 35-44 beta-secretase 1 Homo sapiens 49-54 17610302-5 2007 In the following we report the synthesis of quinoline-based derivatives of pirinixic acid, which in a Gal4-based luciferase-reporter gene assay proved to be potent dual PPARalpha/gamma agonists. quinoline 44-53 peroxisome proliferator activated receptor alpha Homo sapiens 169-178 17610302-3 2007 The goal of this study was to evaluate, whether the PPAR agonism of pirinixic acid may be also maintained in quinoline-based derivatives. quinoline 109-118 peroxisome proliferator activated receptor alpha Homo sapiens 52-56 17610302-4 2007 The present study revealed that the mere substitution of the dimethyl aniline moiety of pirinixic acid by quinoline leads to a total loss of PPARalpha/gamma agonism, whereas concomitant alpha-substitution with n-butyl or n-hexyl groups restores and even enforces PPAR activation, leading to potent dual PPARalpha/gamma agonists. quinoline 106-115 peroxisome proliferator activated receptor alpha Homo sapiens 141-150 17610302-4 2007 The present study revealed that the mere substitution of the dimethyl aniline moiety of pirinixic acid by quinoline leads to a total loss of PPARalpha/gamma agonism, whereas concomitant alpha-substitution with n-butyl or n-hexyl groups restores and even enforces PPAR activation, leading to potent dual PPARalpha/gamma agonists. quinoline 106-115 peroxisome proliferator activated receptor alpha Homo sapiens 141-145 17610302-4 2007 The present study revealed that the mere substitution of the dimethyl aniline moiety of pirinixic acid by quinoline leads to a total loss of PPARalpha/gamma agonism, whereas concomitant alpha-substitution with n-butyl or n-hexyl groups restores and even enforces PPAR activation, leading to potent dual PPARalpha/gamma agonists. quinoline 106-115 peroxisome proliferator activated receptor alpha Homo sapiens 303-312 17391964-2 2007 An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led to the identification of two potent LXR agonists 23 and 27. quinoline 55-64 nuclear receptor subfamily 1, group H, member 3 Mus musculus 122-125 17400452-3 2007 Using an HTS approach, we have identified quinoline-based PDE-10A inhibitors as insulin secretagogues in vitro. quinoline 42-51 phosphodiesterase 10A Homo sapiens 58-65 17275313-1 2007 Schiff bases prepared by the reactions of substituted amines with indole-/, pyrimidine-/, pyridine-/, and quinoline-aldehydes are made to undergo indium mediated allylation whereby a (substituted amine, allyl)methyl group has been introduced at C-3 of indole, C-5 of pyrimidine, and C-2 of pyridine and quinoline. quinoline 106-115 complement C3 Homo sapiens 245-248 17400452-3 2007 Using an HTS approach, we have identified quinoline-based PDE-10A inhibitors as insulin secretagogues in vitro. quinoline 42-51 insulin Homo sapiens 80-87 17257838-1 2007 A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). quinoline 133-142 androgen receptor Homo sapiens 69-86 17275313-1 2007 Schiff bases prepared by the reactions of substituted amines with indole-/, pyrimidine-/, pyridine-/, and quinoline-aldehydes are made to undergo indium mediated allylation whereby a (substituted amine, allyl)methyl group has been introduced at C-3 of indole, C-5 of pyrimidine, and C-2 of pyridine and quinoline. quinoline 106-115 complement C5 Homo sapiens 260-263 17275313-1 2007 Schiff bases prepared by the reactions of substituted amines with indole-/, pyrimidine-/, pyridine-/, and quinoline-aldehydes are made to undergo indium mediated allylation whereby a (substituted amine, allyl)methyl group has been introduced at C-3 of indole, C-5 of pyrimidine, and C-2 of pyridine and quinoline. quinoline 106-115 complement C2 Homo sapiens 283-286 17275313-1 2007 Schiff bases prepared by the reactions of substituted amines with indole-/, pyrimidine-/, pyridine-/, and quinoline-aldehydes are made to undergo indium mediated allylation whereby a (substituted amine, allyl)methyl group has been introduced at C-3 of indole, C-5 of pyrimidine, and C-2 of pyridine and quinoline. quinoline 303-312 complement C3 Homo sapiens 245-248 17275313-1 2007 Schiff bases prepared by the reactions of substituted amines with indole-/, pyrimidine-/, pyridine-/, and quinoline-aldehydes are made to undergo indium mediated allylation whereby a (substituted amine, allyl)methyl group has been introduced at C-3 of indole, C-5 of pyrimidine, and C-2 of pyridine and quinoline. quinoline 303-312 complement C5 Homo sapiens 260-263 17275313-1 2007 Schiff bases prepared by the reactions of substituted amines with indole-/, pyrimidine-/, pyridine-/, and quinoline-aldehydes are made to undergo indium mediated allylation whereby a (substituted amine, allyl)methyl group has been introduced at C-3 of indole, C-5 of pyrimidine, and C-2 of pyridine and quinoline. quinoline 303-312 complement C2 Homo sapiens 283-286 17897030-4 2007 Transposition of the 4-amino group to the 2-position of the quinoline core structure provided the 2-aminoquinoline lead class with similar MCH1R binding affinity. quinoline 60-69 melanin concentrating hormone receptor 1 Homo sapiens 139-144 17188862-2 2007 Variation of the solubilizing amine tail or removal of the methoxy group from either C-6 of the quinoline core or C-5 of the aniline headpiece led to reduced activity. quinoline 96-105 complement C6 Homo sapiens 85-88 17310736-5 2007 Disperse Yellow 64 and 3"-hydroxybenzo[b]quinophthalone are quinoline disperse dyes capable of activating the AhR at nanomolar concentrations. quinoline 60-69 aryl hydrocarbon receptor Homo sapiens 110-113 17310736-7 2007 Quinoline disperse dyes are suggested to be a new class of xenobiotic AhR ligands which pose a danger to aquatic biota and human health. quinoline 0-9 aryl hydrocarbon receptor Homo sapiens 70-73 17201408-4 2007 High-throughput screening of the Wyeth chemical library identified the quinoline salicylic acid class of compounds (1) as antagonists of P-selectin, with potency in in vitro and cell-based assays far superior to that of sLex. quinoline 71-80 selectin P Rattus norvegicus 137-147 16982756-3 2006 In the present study, we show that a quinoline-urea derivative, KRN951, is a novel tyrosine kinase inhibitor for VEGFRs with antitumor angiogenesis and antigrowth activities. quinoline 37-46 kinase insert domain receptor Homo sapiens 113-119 17057854-1 2006 A selective and sensitive fluorescent sensor for detection of Hg2+ in natural water was achieved by incorporating the well-known fluorophore quinoline group and a water-soluble D-glucosamine group within one molecule. quinoline 141-150 polycystin 1, transient receptor potential channel interacting pseudogene 2 Homo sapiens 62-65 17121910-5 2006 We discovered a novel quinoline-urea derivative, Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N"-[1-(1,3-thiazole-2-yl)ethyl]urea), which is a c-Fms tyrosine kinase inhibitor. quinoline 22-31 colony stimulating factor 1 receptor Rattus norvegicus 161-166 17034141-0 2006 Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. quinoline 35-44 adrenoceptor alpha 2C Homo sapiens 81-103 16870427-1 2006 A novel series of substituted quinoline analogs were designed and synthesized as potent and selective melanin concentrating hormone (MCH) antagonists. quinoline 30-39 pro-melanin concentrating hormone Homo sapiens 102-131 16870427-1 2006 A novel series of substituted quinoline analogs were designed and synthesized as potent and selective melanin concentrating hormone (MCH) antagonists. quinoline 30-39 pro-melanin concentrating hormone Homo sapiens 133-136 16495062-1 2006 The previous exploration of the structure-affinity relationships concerning 4-phenyl-2-quinolinecarboxamide peripheral benzodiazepine receptor (PBR) ligands 6 showed as an interesting result the importance of the presence of a chlorine atom in the methylene carbon at position 3 of the quinoline nucleus. quinoline 87-96 translocator protein Rattus norvegicus 108-142 16495062-1 2006 The previous exploration of the structure-affinity relationships concerning 4-phenyl-2-quinolinecarboxamide peripheral benzodiazepine receptor (PBR) ligands 6 showed as an interesting result the importance of the presence of a chlorine atom in the methylene carbon at position 3 of the quinoline nucleus. quinoline 87-96 translocator protein Rattus norvegicus 144-147 16380251-0 2006 Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists. quinoline 45-54 coagulation factor II thrombin receptor Homo sapiens 80-85 16412632-0 2006 BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline. quinoline 122-131 beta-secretase 1 Homo sapiens 0-6 20144051-1 2006 Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. quinoline 44-53 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 117-156 20144051-1 2006 Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. quinoline 44-53 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 173-178 20144051-1 2006 Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. quinoline 44-53 vascular endothelial growth factor A Homo sapiens 183-217 20144051-1 2006 Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. quinoline 44-53 vascular endothelial growth factor A Homo sapiens 219-223 16004972-2 2005 It is already known that the quinoline derivative, MK-571, is a potent inhibitor of MRP-mediated transport. quinoline 29-38 ATP binding cassette subfamily C member 1 Homo sapiens 84-87 16332855-0 2005 Transcriptional activation of quinoline degradation operons of Pseudomonas putida 86 by the AraC/XylS-type regulator OxoS and cross-regulation of the PqorM promoter by XylS. quinoline 30-39 transcriptional activator of xyl-meta pathway operon Pseudomonas putida 97-101 16146413-1 2005 [reaction: see text] Treatment of (Z)-2-pyridine and quinoline silylated vinylacetylenes at reflux with several alcohols in the presence of a suitable inorganic base (KOH, K2CO3, CsF, or KF) serendipitously gave 3-alkoxylmethylindolizines and the corresponding 1-alkoxymethylpyrrolo [1,2-a]quinolines and not the anticipated desilylated vinylacetylene derivatives. quinoline 53-62 colony stimulating factor 2 Homo sapiens 179-182 15737997-0 2005 Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. quinoline 145-154 mitogen-activated protein kinase 14 Mus musculus 84-87 15916432-2 2005 Fifty-two compounds including naphthalene, lactone and quinoline derivatives were assayed in a 96-well plate format for CYP1A2 inhibition activity using 7-ethoxyresorufin O-dealkylation as the probe reaction. quinoline 55-64 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 120-126 15914012-1 2005 Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses were carried out on quinazoline, quinoline, and cyanoquinoline derivatives inhibiting c-Src kinase. quinoline 115-124 C-terminal Src kinase Homo sapiens 168-180 15997102-2 2005 The activity of human CYP2E1 of the microsomes from baculovirus-transfected insect cells expressing recombinant human CYP2E1 was determined by measuring quinoline 3-hydroxylation, which was detectable by fluorescence monitoring (Ex=355 nm and Em=460 nm). quinoline 153-162 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 22-28 15997102-2 2005 The activity of human CYP2E1 of the microsomes from baculovirus-transfected insect cells expressing recombinant human CYP2E1 was determined by measuring quinoline 3-hydroxylation, which was detectable by fluorescence monitoring (Ex=355 nm and Em=460 nm). quinoline 153-162 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 118-124 15997102-3 2005 Diethyldithiocarbamate (DDTC), a specific inhibitor of CYP2E1, potently inhibited quinoline 3-hydroxylation (IC50=8.9 microM). quinoline 82-91 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 55-61 15575775-2 2004 The stability of MC2 is believed to be due to the electron-withdrawing effect of both the quinoline and the trifluoromethyl groups. quinoline 90-99 melanocortin 5 receptor Homo sapiens 17-20 15641113-2 2005 In both complexes, the sp(3) nitrogen of quinuclidine is protonated, whereas the sp(2) nitrogen of quinoline is linked to the Co(II) atom, which coordinates three chlorine atoms in distorted tetrahedral geometry. quinoline 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-132 15777083-2 2005 Both the carcinogenicity and the mutagenicity of quinolone and quinoline derivatives, as determined by SAS, can be attributed to their genotoxicity potential. quinoline 63-72 tetraspanin 31 Homo sapiens 103-106 15689158-0 2005 Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. quinoline 143-152 transient receptor potential cation channel subfamily V member 1 Homo sapiens 6-46 15554077-2 2004 TAK-603 is a new quinoline derivative, which selectively suppresses Th1 cytokine production. quinoline 17-26 negative elongation factor complex member C/D Homo sapiens 68-71 15450938-7 2004 E2F1 protein was suppressed by all differentiation quinolines, but not by non-differentiating analogs, quinoline and primaquine. quinoline 51-60 E2F transcription factor 1 Homo sapiens 0-4 15450938-12 2004 We conclude DNA damage and reductions in E2F1 protein are mechanistically important to the differentiation and antiproliferative activities of these quinoline drug candidates. quinoline 149-158 E2F transcription factor 1 Homo sapiens 41-45 15139763-1 2004 In the course of our studies on non-peptide bradykinin (BK) B(2) receptor ligands, it was suggested that the 4-substituent of the quinoline ring may play a critical role in determining binding affinities for human and guinea pig B(2) receptors, as well as agonist/antagonist properties. quinoline 130-139 kininogen 1 Homo sapiens 44-54 15210071-9 2004 Docking results showed that a carboxyl group at C-7 and a hydroxyl group at C-8 in the quinoline subunit, bound closely to the divalent metal cofactor (Mg2+) around the integrase catalytic site. quinoline 87-96 complement C7 Homo sapiens 48-51 15210071-9 2004 Docking results showed that a carboxyl group at C-7 and a hydroxyl group at C-8 in the quinoline subunit, bound closely to the divalent metal cofactor (Mg2+) around the integrase catalytic site. quinoline 87-96 homeobox C8 Homo sapiens 76-79 15139763-1 2004 In the course of our studies on non-peptide bradykinin (BK) B(2) receptor ligands, it was suggested that the 4-substituent of the quinoline ring may play a critical role in determining binding affinities for human and guinea pig B(2) receptors, as well as agonist/antagonist properties. quinoline 130-139 bradykinin receptor B2 Homo sapiens 60-73 15094204-10 2004 However, weak transcription of ORFs7-9 also occurred independent of quinoline and OxoS. quinoline 68-77 hypothetical protein Pseudomonas putida 31-38 15115408-2 2004 Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B(2) receptor antagonists afforded highly potent ligands for human B(2) receptor with various affinities for guinea pig B(2) receptor, indicating remarkable species difference. quinoline 72-81 bradykinin receptor B2 Homo sapiens 123-136 15115408-2 2004 Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B(2) receptor antagonists afforded highly potent ligands for human B(2) receptor with various affinities for guinea pig B(2) receptor, indicating remarkable species difference. quinoline 72-81 bradykinin receptor B2 Homo sapiens 190-203 15115408-2 2004 Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B(2) receptor antagonists afforded highly potent ligands for human B(2) receptor with various affinities for guinea pig B(2) receptor, indicating remarkable species difference. quinoline 72-81 bradykinin receptor B2 Homo sapiens 190-203 15078100-1 2004 Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol. quinoline 118-127 N-ribosyldihydronicotinamide:quinone reductase 2 Homo sapiens 0-24 12673023-5 2003 Halogen-substitution effects on AhR ligand activity in aza-polycyclic aromatics were also investigated with quinoline, benzo[f]quinoline (BfQ), benzo[h]quinoline (BhQ) and 1,7-phenanthroline (1,7-Phe). quinoline 108-117 aryl hydrocarbon receptor Homo sapiens 32-35 15006407-3 2004 While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. quinoline 62-71 phosphodiesterase 5A Homo sapiens 95-99 14754409-9 2004 PAL of MRP1 was first demonstrated with the quinoline-based drug, IAAQ. quinoline 44-53 ATP binding cassette subfamily C member 1 Homo sapiens 7-11 15078100-1 2004 Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol. quinoline 118-127 N-ribosyldihydronicotinamide:quinone reductase 2 Homo sapiens 26-29 15028260-5 2004 For simple substituents R(2) at the quinoline 2-position, the rates of quinone metabolism by hNQO1 decrease for R(2)=Cl>H approximately Me>Ph. quinoline 36-45 NAD(P)H quinone dehydrogenase 1 Homo sapiens 93-98 15027853-2 2004 Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline moiety of our non-peptide B(2) receptor antagonists resulted in enhancing binding affinities for the human B(2) receptor and reducing binding affinities for the guinea pig one, providing new structural insights into species difference. quinoline 83-92 bradykinin receptor B2 Homo sapiens 119-132 15027853-2 2004 Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline moiety of our non-peptide B(2) receptor antagonists resulted in enhancing binding affinities for the human B(2) receptor and reducing binding affinities for the guinea pig one, providing new structural insights into species difference. quinoline 83-92 bradykinin receptor B2 Homo sapiens 200-213 15027853-3 2004 A CoMFA study focused on the diversity of the quinoline moiety afforded correlative and predictive QSAR models of binding for the human B(2) receptor but not for the guinea pig one. quinoline 46-55 bradykinin receptor B2 Homo sapiens 136-149 14738594-0 2003 Study of inhibition of CYP2A6 by some drugs derived from quinoline. quinoline 57-66 cytochrome P450 2A13 Bos taurus 23-29 14738594-2 2003 Firstly, we measured the inhibition of coumarin 7-hydroxylase of cDNA-expressed human CYP2A6 and in bovine liver microsomes, by quinoline and fluoroquinolines (FQ). quinoline 128-137 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 39-61 14738594-2 2003 Firstly, we measured the inhibition of coumarin 7-hydroxylase of cDNA-expressed human CYP2A6 and in bovine liver microsomes, by quinoline and fluoroquinolines (FQ). quinoline 128-137 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 86-92 14738594-4 2003 This suggests that the position 3 of quinoline is a recognition site for CYP2A6. quinoline 37-46 cytochrome P450 2A13 Bos taurus 73-79 14738594-7 2003 Secondly, we studied the inhibition of CYP2A6 with clinically used drugs of quinoline compounds, such as norfloxacin as an antibacterial agent, quinidine as an antiarrhythmic agent, quinine and chloroquine as antimalaria agents and rebamipide as an anti-ulcer agent. quinoline 76-85 cytochrome P450 2A13 Bos taurus 39-45 12749901-2 2003 SAR studies on the 6,7-dihydroxy moiety of the quinoline 5a showed that the catecol moiety could be replaced with other functional groups. quinoline 47-56 sarcosine dehydrogenase Homo sapiens 0-3 12431079-5 2002 Thus, Mo(PMe3)6 reacts with pyridine to give an eta2-pyridyl derivative [eta2-(C5H4N)]Mo(PMe3)4H as a result of alpha-C-H bond cleavage, whereas quinoline and acridine give products of the type (eta6-ArH)Mo(PMe3)3 in which both ligands coordinate in an eta6-manner. quinoline 145-154 DNA polymerase iota Homo sapiens 48-52 12431079-5 2002 Thus, Mo(PMe3)6 reacts with pyridine to give an eta2-pyridyl derivative [eta2-(C5H4N)]Mo(PMe3)4H as a result of alpha-C-H bond cleavage, whereas quinoline and acridine give products of the type (eta6-ArH)Mo(PMe3)3 in which both ligands coordinate in an eta6-manner. quinoline 145-154 DNA polymerase iota Homo sapiens 73-77 12082016-8 2002 Tp53 was also strongly induced by an N-oxide of quinoline and by dabequine, an experimental antimalarial evaluated in humans; dabequine was reported to be negative in other screens of mutagenicity and clastogenicity but carcinogenic in animal studies. quinoline 48-57 tumor protein p53 Homo sapiens 0-4 11863435-9 2002 Furthermore, both tacrine and huprine X bind more tightly to Torpedo than to human AChE, suggesting that their quinoline substructures interact better with Phe330 than with Tyr337, the corresponding residue in the human AChE structure. quinoline 111-120 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-87 11863435-9 2002 Furthermore, both tacrine and huprine X bind more tightly to Torpedo than to human AChE, suggesting that their quinoline substructures interact better with Phe330 than with Tyr337, the corresponding residue in the human AChE structure. quinoline 111-120 acetylcholinesterase (Cartwright blood group) Homo sapiens 220-224 11849097-1 2002 The bifunctional complex [Ru(TAP)(2)POQ-Nmet](2+), 1, formed with a [Ru(TAP)(2)Phen](2+) metallic unit linked to a quinoline moiety, and [Ru(TAP)(2)Phen](2+), 2, as reference, have been tested as photoprobes of DNA. quinoline 115-124 tracheal antimicrobial peptide Bos taurus 29-32 11557359-0 2001 Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. quinoline 40-49 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-73 11728194-2 2001 The preliminary structure-activity relationship of nonaromatic C-5 substitution on the tetracyclic quinoline core showed a preference for small lipophilic side chains. quinoline 99-108 complement C5 Homo sapiens 63-66 11470516-8 2001 Both YOR273C and TPO1 as well as at least one other determinant involved in the yeast pleiotropic drug resistance network contribute to resistance to a quinoline-containing antimalarial drug. quinoline 152-161 Tpo1p Saccharomyces cerevisiae S288C 17-21 11520196-0 2001 Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity. quinoline 99-108 nuclear receptor subfamily 3 group C member 1 Homo sapiens 64-87 11473730-0 2001 A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. quinoline 6-15 ATP binding cassette subfamily B member 1 Homo sapiens 102-116 11473730-2 2001 MS-209 is a novel quinoline compound, which reverses P-glycoprotein (P-gp)-mediated MDR. quinoline 18-27 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 11473730-2 2001 MS-209 is a novel quinoline compound, which reverses P-glycoprotein (P-gp)-mediated MDR. quinoline 18-27 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 11356103-0 2001 Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. quinoline 90-99 tachykinin receptor 2 Homo sapiens 40-61 11399172-2 2001 Both head-to-head (HTH) and head-to-tail (HTT) rotamer forms are found in the crystal structure of cis-[PtCl(2)(quinoline)(2)]. quinoline 112-121 huntingtin Homo sapiens 42-45 11354380-0 2001 Syntheses and evaluation of quinoline derivatives as novel retinoic acid receptor alpha antagonists. quinoline 28-37 retinoic acid receptor alpha Homo sapiens 59-87 10961395-2 2000 In a domino reaction, substituted quinoline derivatives are obtained in the presence of cationic rhodium complexes, such as [Rh(cod)2]BF4, and PPh3. quinoline 34-43 protein phosphatase 4 catalytic subunit Homo sapiens 143-147 11312914-8 2001 The most potent compound, among the newly synthesized ones, shows a nanomolar PBR affinity similar to that shown by 1 and the presence of a basic N-ethyl-N-benzylaminomethyl group in 3-position of the quinoline nucleus. quinoline 201-210 translocator protein Homo sapiens 78-81 11208926-4 2001 In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes. quinoline 41-50 ATP binding cassette subfamily C member 1 Rattus norvegicus 114-118 11208926-4 2001 In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes. quinoline 41-50 ATP binding cassette subfamily C member 2 Rattus norvegicus 123-127 11208926-4 2001 In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes. quinoline 41-50 ATP binding cassette subfamily C member 1 Rattus norvegicus 302-306 11208926-4 2001 In the presence of cyclosporin A and the quinoline-derivative MK571, inhibitors of multidrug resistance proteins (MRP1 and MRP2), glutathione disulfide accumulated in cells and the release of glutathione disulfide from astrocytes during H2O2 stress was potently inhibited, suggesting a contribution of MRP1 or MRP2 in the release of glutathione disulfide from astrocytes. quinoline 41-50 ATP binding cassette subfamily C member 2 Rattus norvegicus 310-314 11193386-2 2000 Quinoline, a hepatocarcinogen, mutates bacterial tester strains in the presence of rat liver microsomal enzymes and induces GST-P (placental glutathione S-transferase)-positive foci in a medium-term bioassay system for hepatocarcinogenesis. quinoline 0-9 glutathione S-transferase pi 1 Rattus norvegicus 124-129 11193386-2 2000 Quinoline, a hepatocarcinogen, mutates bacterial tester strains in the presence of rat liver microsomal enzymes and induces GST-P (placental glutathione S-transferase)-positive foci in a medium-term bioassay system for hepatocarcinogenesis. quinoline 0-9 hematopoietic prostaglandin D synthase Rattus norvegicus 141-166 10736425-0 2000 Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. quinoline 53-62 ATP binding cassette subfamily C member 3 Homo sapiens 12-15 10821682-0 2000 The multidrug resistance protein is photoaffinity labeled by a quinoline-based drug at multiple sites. quinoline 63-72 ATP binding cassette subfamily C member 1 Homo sapiens 4-32 10821682-7 2000 Furthermore, a molar excess of leukotriene C(4), doxorubicin, colchicine, and other quinoline-based drugs, including MK571, inhibited the photoaffinity labeling of the MRP. quinoline 84-93 ATP binding cassette subfamily C member 1 Homo sapiens 168-171 10736425-2 2000 We have demonstrated previously direct binding between MRP and a quinoline-based photoreactive drug (iodo-azido-amino quinoline, IAAQ) (Vezmar et al., Biochem Biophys Res Commun 241: 104-111, 1997). quinoline 65-74 ATP binding cassette subfamily C member 3 Homo sapiens 55-58 10736425-3 2000 In this report, we show the reversal of multidrug resistance in two MRP-overexpressing cell lines, HL60/AR and H69/AR, with four quinoline-based drugs. quinoline 129-138 ATP binding cassette subfamily C member 3 Homo sapiens 68-71 10780910-3 2000 Regarding the in vitro experiments, the structural requirements for biological activity are a carboxyl group at C-7, a hydroxyl group at C-8 in the quinoline subunit, and an ancillary phenyl ring. quinoline 148-157 homeobox C8 Homo sapiens 137-140 10443017-0 1999 Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists. quinoline 19-28 tachykinin receptor 3 Homo sapiens 71-84 10511127-0 1999 Pharmacologic profiles of GA0113, a novel quinoline derivative angiotensin II AT1-receptor antagonist. quinoline 42-51 angiotensinogen Rattus norvegicus 63-77 10511127-1 1999 GA0113 is a newly developed angiotensin II (Ang II) AT1-receptor antagonist having a quinoline moiety. quinoline 85-94 angiotensinogen Rattus norvegicus 28-42 10511127-1 1999 GA0113 is a newly developed angiotensin II (Ang II) AT1-receptor antagonist having a quinoline moiety. quinoline 85-94 angiotensinogen Rattus norvegicus 44-50 10511127-1 1999 GA0113 is a newly developed angiotensin II (Ang II) AT1-receptor antagonist having a quinoline moiety. quinoline 85-94 angiotensin II receptor, type 1a Rattus norvegicus 52-55 10443017-3 1999 In particular, it is highlighted that both the benzene-condensed ring and the quinoline nitrogen are crucial determinants for optimal binding affinity to the hNK-3 receptor. quinoline 78-87 tachykinin receptor 3 Homo sapiens 158-172 10329466-7 1999 The results indicate that the ability of the quinoline-linked TP analogues to inhibit ALS is highly sensitive to substitution at the ortho position (C-7) and to the position of the ring nitrogen around the sulfonamide functionality (C-8). quinoline 45-54 probable glutathione S-transferase Nicotiana tabacum 149-152 9554877-5 1998 Incorporation of this amino acid residue into the model revealed additional interactions between the guanidine group and the nitrogen atoms of quinoline-containing CysLT1 antagonists. quinoline 143-152 cysteinyl leukotriene receptor 1 Homo sapiens 164-170 10090788-5 1999 Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. quinoline 49-58 NK3 homeobox 1 Homo sapiens 138-143 10090788-5 1999 Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. quinoline 49-58 NK3 homeobox 1 Homo sapiens 185-190 10090788-5 1999 Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. quinoline 49-58 tachykinin receptor 2 Homo sapiens 202-207 10049760-0 1999 Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. quinoline 29-38 ATP binding cassette subfamily C member 1 Homo sapiens 63-91 10049760-0 1999 Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. quinoline 29-38 ATP binding cassette subfamily C member 1 Homo sapiens 93-96 15825294-4 1998 The RTP intensity was linear for quinoline/beta-CD/DBP systems with quinoline concentration in the ranges of 5.0 x 10(-7)-5.0 x 10(-5)mol/L and 5.0 x 10(-5)-5.0 x 10(-4)mol/L, respectively. quinoline 68-77 MORN repeat containing 4 Homo sapiens 4-7 15825294-1 1998 A cyclodextrininduced-room temperature phosphorescence (CD-RTP) system for the determination of quinoline without deoxidization procedure was developed based on the external heavy atom effect of dibromopropane (DBP), the RTP maximum wavelengths lambda(ex)/lambda(em) = 273/496nm. quinoline 96-105 MORN repeat containing 4 Homo sapiens 59-62 15825294-1 1998 A cyclodextrininduced-room temperature phosphorescence (CD-RTP) system for the determination of quinoline without deoxidization procedure was developed based on the external heavy atom effect of dibromopropane (DBP), the RTP maximum wavelengths lambda(ex)/lambda(em) = 273/496nm. quinoline 96-105 MORN repeat containing 4 Homo sapiens 221-224 15825294-4 1998 The RTP intensity was linear for quinoline/beta-CD/DBP systems with quinoline concentration in the ranges of 5.0 x 10(-7)-5.0 x 10(-5)mol/L and 5.0 x 10(-5)-5.0 x 10(-4)mol/L, respectively. quinoline 33-42 MORN repeat containing 4 Homo sapiens 4-7 9929169-2 1998 We found that metabolic activation of one of these heterocyclic amines, the quinoline derivative 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), can be catalyzed by prostaglandin H synthase (PHS) as well as by CYP1A2. quinoline 76-85 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 208-214 9751078-3 1998 We recently demonstrated the direct binding of a quinoline-based photoactive drug, N-[4-[1-hydroxy-2-(dibutylamino)ethyl]quinolin-8-yl]-4-az idosalicylamide (IAAQ), to MRP at a biologically relevant site [Vezmar et al., Biochem Biophys Res Commun 241: 104-111, 1997]. quinoline 49-58 ATP binding cassette subfamily C member 1 Homo sapiens 168-171 9630605-1 1998 Quinoline, a hepatocarcinogen, mutates the bacterial tester strains in the presence of the rat liver microsomal enzymes and induces GST-P (placental glutathione S-transferase)-positive foci in a medium-term bioassay system for hepatocarcinogenesis. quinoline 0-9 glutathione S-transferase pi 1 Rattus norvegicus 132-137 9630605-1 1998 Quinoline, a hepatocarcinogen, mutates the bacterial tester strains in the presence of the rat liver microsomal enzymes and induces GST-P (placental glutathione S-transferase)-positive foci in a medium-term bioassay system for hepatocarcinogenesis. quinoline 0-9 hematopoietic prostaglandin D synthase Rattus norvegicus 149-174 9788575-1 1998 PURPOSE AND METHODS: To develop a clinically useful approach to circumvent P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in MDR human small-cell lung cancer (SCLC), we examined the ability of a novel quinoline compound, MS-209, to reverse MDR by inhibition of P-gp function in combination with other MDR-reversing drugs using a cytotoxicity assay. quinoline 212-221 ATP binding cassette subfamily B member 1 Homo sapiens 75-89 10099493-0 1998 A convenient method for library construction: parallel synthesis of beta-amino ester and quinoline derivatives in liquid phase using Ln(OTf)3-catalyzed three-component reactions A convenient method for library construction in liquid phase, which is based on lanthanide triflate (Ln(OTf)3)-catalyzed three-component reactions, has been developed. quinoline 89-98 POU class 5 homeobox 1 Homo sapiens 136-141 9871521-0 1998 Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class. quinoline 84-93 sarcosine dehydrogenase Homo sapiens 14-17 9788575-1 1998 PURPOSE AND METHODS: To develop a clinically useful approach to circumvent P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in MDR human small-cell lung cancer (SCLC), we examined the ability of a novel quinoline compound, MS-209, to reverse MDR by inhibition of P-gp function in combination with other MDR-reversing drugs using a cytotoxicity assay. quinoline 212-221 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 9013804-7 1997 The number and areas of GST-P (placental glutathione S-transferase)-positive foci induced in the liver increased significantly as a result of treatment with 0.1% quinoline, and this increase was dramatic with 5-FQ at both doses, whereas no increases were noted with 3-FQ at either dose. quinoline 162-171 glutathione S-transferase pi 1 Rattus norvegicus 24-29 9061206-1 1997 The present paper describes the structural modifications leading to the discovery of a new series of quinoline-containing cys-LT1 receptor (LTD4 receptor) antagonists. quinoline 101-110 cysteinyl leukotriene receptor 1 Cavia porcellus 140-153 9405241-0 1997 The quinoline-based drug, N-[4-[1-hydroxy-2-(dibutylamino)ethyl] quinolin-8-yl]-4-azidosalicylamide, photoaffinity labels the multidrug resistance protein (MRP) at a biologically relevant site. quinoline 4-13 ATP binding cassette subfamily C member 1 Homo sapiens 126-154 9405241-0 1997 The quinoline-based drug, N-[4-[1-hydroxy-2-(dibutylamino)ethyl] quinolin-8-yl]-4-azidosalicylamide, photoaffinity labels the multidrug resistance protein (MRP) at a biologically relevant site. quinoline 4-13 ATP binding cassette subfamily C member 1 Homo sapiens 156-159 9405241-3 1997 In this report, we describe the interactions of a quinoline-based drug, N-{4-[1-hydroxy-2-(dibutylamino)ethyl] quinolin-8-yl}-4-azidosalicylamide (IAAQ), with MRP. quinoline 50-59 ATP binding cassette subfamily C member 1 Homo sapiens 159-162 9013804-7 1997 The number and areas of GST-P (placental glutathione S-transferase)-positive foci induced in the liver increased significantly as a result of treatment with 0.1% quinoline, and this increase was dramatic with 5-FQ at both doses, whereas no increases were noted with 3-FQ at either dose. quinoline 162-171 hematopoietic prostaglandin D synthase Rattus norvegicus 41-66 8575032-5 1995 Heteroaromatic rings such as pyrrole, thiophene, furan, pyridine, pyridazine, 1,2-benzisoxazole, indole, quinoline, and isoquinoline rings showed weak 5-HT3 receptor antagonistic activity. quinoline 105-114 5-hydroxytryptamine receptor 3A Rattus norvegicus 151-165 8824525-0 1996 Cytochrome P450 species involved in the metabolism of quinoline. quinoline 54-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-15 8824525-2 1996 The specific cytochrome P450 enzymes involved in quinoline metabolism in human and rat liver microsomes were determined using cDNA-expressed cytochrome P450s, correlations with specific cytochrome P450-linked monooxygenase activities in human liver microsomes and inhibition by specific inhibitors and antibodies. quinoline 49-58 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 13-28 8824525-2 1996 The specific cytochrome P450 enzymes involved in quinoline metabolism in human and rat liver microsomes were determined using cDNA-expressed cytochrome P450s, correlations with specific cytochrome P450-linked monooxygenase activities in human liver microsomes and inhibition by specific inhibitors and antibodies. quinoline 49-58 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 141-156 9272120-0 1997 A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. quinoline 8-17 ATP binding cassette subfamily C member 3 Homo sapiens 106-145 9272120-0 1997 A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. quinoline 8-17 ATP binding cassette subfamily C member 3 Homo sapiens 147-150 9272120-1 1997 PURPOSE AND METHODS: MS-209 is a newly synthesized quinoline compound used orally to overcome human P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). quinoline 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 100-114 9272120-1 1997 PURPOSE AND METHODS: MS-209 is a newly synthesized quinoline compound used orally to overcome human P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). quinoline 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 116-119 8605195-9 1996 Other aromatic and fused polycyclic and heterocyclic aldehydes, as well as derivatives of coumarin, quinoline, indole, and pyridine, are tight-binding, slow-turnover substrates for ALDH-2 and relatively weak inhibitors of ALDH-1. quinoline 100-109 aldehyde dehydrogenase 2 family member Homo sapiens 181-187 8605195-9 1996 Other aromatic and fused polycyclic and heterocyclic aldehydes, as well as derivatives of coumarin, quinoline, indole, and pyridine, are tight-binding, slow-turnover substrates for ALDH-2 and relatively weak inhibitors of ALDH-1. quinoline 100-109 aldehyde dehydrogenase 1 family member A1 Homo sapiens 222-228 7811392-5 1994 Quinacrine and the quinoline-based antimalarials variously inhibit CDPK, PKC and MLCK albeit at relatively high concentrations (about 1 to 4 x 10(-4) M), the best inhibitors found being primaquine, pentaquine and mefloquine (IC50 values for MLCK 49, 103 and 33 microM, respectively). quinoline 19-28 myosin light chain kinase 3 Rattus norvegicus 81-85 7492265-1 1995 The 5-HT1A receptor affinities and ionization constants of a set of 1-arylpiperazine (4) 1,2,3,4-tetrahydroisoquinoline (6), and -quinoline (7) containing N-(omega-arylalkyl) or N-(E)-cinnamyl substituents as well as two morpholine derivatives (8a, 8b) were determined. quinoline 129-139 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 7634376-1 1995 MS-209 is a novel quinoline compound which can overcome multidrug resistance (MDR) both in vitro and in vivo, while having a low level of side effects, and is now being evaluated in a clinical phase II study. quinoline 18-27 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 78-81 7612596-10 1995 Calculations indicate that the benzothiazole ring system is twisted relative to the quinoline in the uncomplexed TOTO molecule. quinoline 84-93 HOP homeobox Homo sapiens 113-117 7648404-9 1995 This quinoline-carboxylic acid derivative is a potent inhibitor of DHOdehase and has proven anti-proliferative activity. quinoline 5-14 dihydroorotate dehydrogenase (quinone) Rattus norvegicus 67-76 7741044-3 1994 The 5-LOX selective and orally active quinoline LSI, BAY X 1005, shares many mechanistic features with the indole LSI, MK-886. quinoline 38-47 lysyl oxidase Homo sapiens 6-9 7811392-5 1994 Quinacrine and the quinoline-based antimalarials variously inhibit CDPK, PKC and MLCK albeit at relatively high concentrations (about 1 to 4 x 10(-4) M), the best inhibitors found being primaquine, pentaquine and mefloquine (IC50 values for MLCK 49, 103 and 33 microM, respectively). quinoline 19-28 myosin light chain kinase 3 Rattus norvegicus 241-245 8273578-3 1993 Indeed, covalent attachment of a quinoline ring to the methoxy substituent of indomethacin affords WAY-122,220 which is almost an order of magnitude more potent than indomethacin in inhibiting human synovial fluid PLA2 (IC50 = 15 and 145 microM, respectively). quinoline 33-42 phospholipase A2 group IB Homo sapiens 214-218 8031320-0 1994 Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. quinoline 88-97 arachidonate 5-lipoxygenase Homo sapiens 41-55 8031320-0 1994 Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. quinoline 88-97 arachidonate 5-lipoxygenase Homo sapiens 183-197 8031320-4 1994 At first sight this finding was not surprising since we have shown earlier that in intact cells this class of quinoline derivatives shares the same mode of action as MK-886, i.e. an indirect inhibition of 5-LOX activity by binding to FLAP. quinoline 110-119 lysyl oxidase Homo sapiens 207-210 8483833-3 1993 In addition, two compounds with a substituted quinoline [LK10; ArCH = (4-hydroxy-7-trifluoromethylquinolin-3-yl)methylene] or isoquinoline (LK11; ArCH = (5-nitroisoquinolin-1-yl)methylene] moiety were synthesized through multiple-step reactions involving reduction and/or oxidation. quinoline 46-55 zinc finger and BTB domain containing 8 opposite strand Homo sapiens 63-67 1748650-4 1991 Selectivity of inhibition of 5-lipoxygenase translocation in both fMLP- or A23187-challenged cells is shown using the indole L-583,916 and quinoline L-671,480, which neither inhibit leukotriene synthesis nor inhibit 5-lipoxygenase translocation. quinoline 139-148 arachidonate 5-lipoxygenase Homo sapiens 29-43 1495009-0 1992 Quinoline antifolate thymidylate synthase inhibitors: variation of the C2- and C4-substituents. quinoline 0-9 thymidylate synthase Mus musculus 21-41 1495009-1 1992 Modifications to the bicyclic ring system of the potent thymidylate synthase (TS) inhibitor N-[4-[N-[(2-amino-3,4-dihydro-4-oxo-6- quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamic acid (1, CB3717) have led to the synthesis of a series of quinoline antifolates bearing a variety of substituents at the C2 and C4 positions. quinoline 249-258 thymidylate synthase Mus musculus 56-76 1313877-1 1992 This report describes the development of a series of highly potent quinoline-based leukotriene D4 (LTD4) receptor antagonists containing an N-benzyl-substituted phenyltetrazole moiety. quinoline 67-76 cysteinyl leukotriene receptor 1 Cavia porcellus 83-113 1857337-0 1991 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. quinoline 53-62 arachidonate 5-lipoxygenase Homo sapiens 0-14 1857337-6 1991 The abilities of the quinoline inhibitors to interact with FLAP correlated well with their abilities to inhibit leukotriene synthesis in human polymorphonuclear leukocytes. quinoline 21-30 arachidonate 5-lipoxygenase activating protein Homo sapiens 59-63 2165582-1 1990 Previous studies have shown that in lipopolysaccharide (LPS)--stimulated human monocytes, interleukin-1 (IL-1) production is altered by quinoline derivative antibiotics (quinolones), in a way which depends both on the dose and on the agents used. quinoline 136-145 interleukin 1 alpha Homo sapiens 90-103 2160861-1 1990 We previously reported that ciprofloxacin (Cip), a quinoline-derivative antibiotic, decreases the biological activity of IL-1 released by LPS-stimulated monocytes after 24 hr of culture without affecting cell-associated IL-1 activity. quinoline 51-60 interleukin 1 beta Homo sapiens 121-125 2165582-1 1990 Previous studies have shown that in lipopolysaccharide (LPS)--stimulated human monocytes, interleukin-1 (IL-1) production is altered by quinoline derivative antibiotics (quinolones), in a way which depends both on the dose and on the agents used. quinoline 136-145 interleukin 1 alpha Homo sapiens 105-109 1689279-1 1990 Previous studies have shown that in lipopolysaccharide (LPS)-stimulated human monocytes, interleukin 1 (IL-1) production is altered by quinoline derivative antibiotics (quinolones), in a way which depends both on the dose and on the agents used. quinoline 135-144 interleukin 1 alpha Homo sapiens 89-108 34743943-0 2021 Physico-chemical investigations of human olfactory receptors OR10G4 and OR2B11 activated by vanillin, ethyl vanillin, coumarin and quinoline molecules using statistical physics method. quinoline 131-140 olfactory receptor family 10 subfamily G member 4 Homo sapiens 61-67 21702715-8 2011 Lipophilic BPs and new classes of non-BP FPPS inhibitors (salicylic acid and quinoline derivatives) have been introduced as possible alternatives for treatment of soft tissue diseases, such as some cancers. quinoline 77-86 farnesyl diphosphate synthase Homo sapiens 41-45 34979735-0 2021 In silico Modeling and Toxicity Profiling of a Set of Quinoline Derivatives as c-MET Inhibitors in the treatment of Human Tumors. quinoline 54-63 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 79-84 34979735-2 2021 There are three aims of the present study: (1) To develop a robust and validated quantitative structure-activity relationship model to predict the c-Met kinase inhibition; (2) to examine the toxicity profiles of these compounds; (3) to design new quinoline derivatives and apply the developed model on these compounds to observe its pertinence. quinoline 247-256 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 147-152 34939319-0 2022 Design, Synthesis and Molecular Modeling of Quinoline Based Derivatives as Anti-Breast Cancer Agents Targeting EGFR/AKT Signaling Pathway. quinoline 44-53 epidermal growth factor receptor Homo sapiens 111-115 34939319-0 2022 Design, Synthesis and Molecular Modeling of Quinoline Based Derivatives as Anti-Breast Cancer Agents Targeting EGFR/AKT Signaling Pathway. quinoline 44-53 AKT serine/threonine kinase 1 Homo sapiens 116-119 34890995-5 2022 Among these quinolin-2(1H)-one derivatives, compound 7a allowed 16.7% of V30M-TTR (3.6 muM) fibril formation at the same concentration and 49.6% at a concentration of 1.8 muM. quinoline 12-20 transthyretin Homo sapiens 78-81 34951581-11 2022 RESULTS: The synthesized quinoline and chromene derivatives were evaluated toward c-Met enzyme using foretinib as the positive control the obtained results showed that twelve compounds exhibited IC50 values less than 1.30 nM. quinoline 25-34 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 82-87 34743943-2 2021 A statistical physics modeling using the monolayer model with identical and independent binding sites of the responses of the two human olfactory receptors OR10G4 and OR2B11 showed that vanillin and quinoline were adsorbed with a mixed non-parallel and parallel orientation on OR10G4 and on OR2B11, respectively. quinoline 199-208 olfactory receptor family 10 subfamily G member 4 Homo sapiens 156-162 34743943-2 2021 A statistical physics modeling using the monolayer model with identical and independent binding sites of the responses of the two human olfactory receptors OR10G4 and OR2B11 showed that vanillin and quinoline were adsorbed with a mixed non-parallel and parallel orientation on OR10G4 and on OR2B11, respectively. quinoline 199-208 olfactory receptor family 2 subfamily B member 11 Homo sapiens 167-173 34743943-0 2021 Physico-chemical investigations of human olfactory receptors OR10G4 and OR2B11 activated by vanillin, ethyl vanillin, coumarin and quinoline molecules using statistical physics method. quinoline 131-140 olfactory receptor family 2 subfamily B member 11 Homo sapiens 72-78 34743943-2 2021 A statistical physics modeling using the monolayer model with identical and independent binding sites of the responses of the two human olfactory receptors OR10G4 and OR2B11 showed that vanillin and quinoline were adsorbed with a mixed non-parallel and parallel orientation on OR10G4 and on OR2B11, respectively. quinoline 199-208 olfactory receptor family 10 subfamily G member 4 Homo sapiens 277-283 34743943-2 2021 A statistical physics modeling using the monolayer model with identical and independent binding sites of the responses of the two human olfactory receptors OR10G4 and OR2B11 showed that vanillin and quinoline were adsorbed with a mixed non-parallel and parallel orientation on OR10G4 and on OR2B11, respectively. quinoline 199-208 olfactory receptor family 2 subfamily B member 11 Homo sapiens 291-297 34807203-1 2021 An efficient Rh(III)-catalyzed straightforward strategy is developed for the synthesis of quinoline braced cyclophane macrocycles via methyl (sp3) C-H functionalization. quinoline 90-99 Sp3 transcription factor Homo sapiens 142-145 34743943-4 2021 The adsorption energy values collected from data analysis, which were ranged from 12.51 to 20.91 kJ/mol, confirmed that the adsorption of vanillin and ethyl vanillin on OR10G4 and the adsorption of coumarin and quinoline on OR2B11were exothermic and were based on physical interactions. quinoline 211-220 olfactory receptor family 2 subfamily B member 11 Homo sapiens 224-230 34743943-5 2021 Furthermore, the dose-olfactory response curves of vanillin, ethyl vanillin, coumarin and quinoline provided access to OR10G4 and OR2B11 steric characterization via the calculation of the studied olfactory receptors site size distributions (RSDs). quinoline 90-99 olfactory receptor family 10 subfamily G member 4 Homo sapiens 119-125 34743943-5 2021 Furthermore, the dose-olfactory response curves of vanillin, ethyl vanillin, coumarin and quinoline provided access to OR10G4 and OR2B11 steric characterization via the calculation of the studied olfactory receptors site size distributions (RSDs). quinoline 90-99 olfactory receptor family 2 subfamily B member 11 Homo sapiens 130-136 34812447-0 2021 Chemically robust and readily available quinoline-based PNN iron complexes: application in C-H borylation of arenes. quinoline 40-49 pinin, desmosome associated protein Homo sapiens 56-59 34812447-4 2021 In this context, our group previously developed a new family of quinoline-based PNN pincer-type ligands for low- to mid-valent iron catalysts. quinoline 64-73 pinin, desmosome associated protein Homo sapiens 80-83 34626785-0 2021 A quinoline derived D-A-D type fluorescent probe for sensing tetrameric transthyretin. quinoline 2-11 transthyretin Homo sapiens 72-85 34873844-0 2022 Quinoline-based thiazolidinone derivatives as potent cytotoxic and apoptosis-inducing agents through EGFR inhibition. quinoline 0-9 epidermal growth factor receptor Homo sapiens 101-105 34873844-2 2022 Hence, ten quinoline-based thiazolidinone derivatives were evaluated for their anticancer activity through cytotoxic activity, epidermal growth factor receptor (EGFR) inhibition pathway, apoptosis investigation through flow cytometric analyses, RT-PCR gene expression, in vivo solid-Ehrlich carcinoma model, and finally in silico approach for highlighting the interaction pose. quinoline 11-20 epidermal growth factor receptor Homo sapiens 127-159 34873844-2 2022 Hence, ten quinoline-based thiazolidinone derivatives were evaluated for their anticancer activity through cytotoxic activity, epidermal growth factor receptor (EGFR) inhibition pathway, apoptosis investigation through flow cytometric analyses, RT-PCR gene expression, in vivo solid-Ehrlich carcinoma model, and finally in silico approach for highlighting the interaction pose. quinoline 11-20 epidermal growth factor receptor Homo sapiens 161-165 33100043-5 2021 The most promising hit was the quinoline derivative VS13, a nanomolar inhibitor of HDAC6, which exhibited a good antiproliferative effect on UM cell lines at micromolar concentration and a capability to modify the mRNA levels of HDAC target genes similar to that of SAHA. quinoline 31-40 histone deacetylase 6 Homo sapiens 83-88 33161799-2 2021 The results indicated that substitution at C3 of quinoline is favoured for HDAC6 selectivity. quinoline 49-58 histone deacetylase 6 Homo sapiens 75-80 34626785-2 2021 In this study, a quinoline-derived D-A-D type chemosensor was rationally designed and synthesized as a probe for the sensitive detection of tetrameric transthyretin (WT-TTR). quinoline 17-26 transthyretin Homo sapiens 151-164 34626785-2 2021 In this study, a quinoline-derived D-A-D type chemosensor was rationally designed and synthesized as a probe for the sensitive detection of tetrameric transthyretin (WT-TTR). quinoline 17-26 transthyretin Homo sapiens 169-172 34770983-0 2021 Hybrid Quinoline-Thiosemicarbazone Therapeutics as a New Treatment Opportunity for Alzheimer"s Disease-Synthesis, In Vitro Cholinesterase Inhibitory Potential and Computational Modeling Analysis. quinoline 7-16 butyrylcholinesterase Homo sapiens 123-137 34760201-1 2021 Pyridine and quinoline undergo selective C-H activation in the 2-position with Rh and Ir complexes of a boryl/bis(phosphine) PBP pincer ligand, resulting in a 2-pyridyl bridging the transition metal and the boron center. quinoline 13-22 polycystin 1, transient receptor potential channel interacting Homo sapiens 125-128 34364055-0 2021 Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). quinoline 84-93 epidermal growth factor receptor Homo sapiens 149-153 34531265-2 2021 Methods: Forty-one patients who underwent gallium-68-conjugated quinoline-based FAP inhibitor (68Ga-FAPI-04) PET/CT for non-cardiovascular indications were retrospectively analyzed. quinoline 64-73 fibroblast activation protein alpha Homo sapiens 80-83 34393265-8 2021 We tested the stability of the docked complexes by running Molecular Dynamics (MD) simulations where we observed the stability of the quinoline analogues with the Spike-ACE2 and TMPRSS2 nevertheless the quinolines were not stable with the Spike protein alone. quinoline 134-143 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 163-168 34393265-8 2021 We tested the stability of the docked complexes by running Molecular Dynamics (MD) simulations where we observed the stability of the quinoline analogues with the Spike-ACE2 and TMPRSS2 nevertheless the quinolines were not stable with the Spike protein alone. quinoline 134-143 angiotensin converting enzyme 2 Homo sapiens 169-173 34393265-8 2021 We tested the stability of the docked complexes by running Molecular Dynamics (MD) simulations where we observed the stability of the quinoline analogues with the Spike-ACE2 and TMPRSS2 nevertheless the quinolines were not stable with the Spike protein alone. quinoline 134-143 transmembrane serine protease 2 Homo sapiens 178-185 34416508-4 2021 These quinoline derivatives had IC50 (microM) values in the range of 0.20-1.75, 0.77-2.20, 0.36-5.50 and 0.90-1.82 for NTPDase1, NTPDase2, NTPDase3 and NTPDase8, respectively. quinoline 6-15 ectonucleoside triphosphate diphosphohydrolase 1 Homo sapiens 119-127 34416508-4 2021 These quinoline derivatives had IC50 (microM) values in the range of 0.20-1.75, 0.77-2.20, 0.36-5.50 and 0.90-1.82 for NTPDase1, NTPDase2, NTPDase3 and NTPDase8, respectively. quinoline 6-15 ectonucleoside triphosphate diphosphohydrolase 2 Homo sapiens 129-137 34416508-4 2021 These quinoline derivatives had IC50 (microM) values in the range of 0.20-1.75, 0.77-2.20, 0.36-5.50 and 0.90-1.82 for NTPDase1, NTPDase2, NTPDase3 and NTPDase8, respectively. quinoline 6-15 ectonucleoside triphosphate diphosphohydrolase 3 Homo sapiens 139-147 34416508-4 2021 These quinoline derivatives had IC50 (microM) values in the range of 0.20-1.75, 0.77-2.20, 0.36-5.50 and 0.90-1.82 for NTPDase1, NTPDase2, NTPDase3 and NTPDase8, respectively. quinoline 6-15 ectonucleoside triphosphate diphosphohydrolase 8 Homo sapiens 152-160 34376582-0 2021 Potent Synergistic Effect on c-Myc Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor. quinoline 94-103 MYC proto-oncogene, bHLH transcription factor Homo sapiens 29-34 34376582-0 2021 Potent Synergistic Effect on c-Myc Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor. quinoline 94-103 polo like kinase 1 Homo sapiens 111-115 34638433-6 2021 Therefore, quinoline-based FAP inhibitors (FAPIs) bind with a high affinity not only to tumors but also to a variety of benign pathologic processes. quinoline 11-20 fibroblast activation protein alpha Homo sapiens 27-30 34333394-9 2021 The pilot screen of ~6,000 compounds of a bioactive chemical library followed by multiple secondary and orthogonal assays revealed a quinoline derivative SGI-1027 as a potent inhibitor of MKK3-MYC PPI. quinoline 133-142 mitogen-activated protein kinase kinase 3 Homo sapiens 188-192 34333394-9 2021 The pilot screen of ~6,000 compounds of a bioactive chemical library followed by multiple secondary and orthogonal assays revealed a quinoline derivative SGI-1027 as a potent inhibitor of MKK3-MYC PPI. quinoline 133-142 MYC proto-oncogene, bHLH transcription factor Homo sapiens 193-196 34630959-0 2021 Synthesis and biological evaluation of novel quinoline analogs of ketoprofen as multidrug resistance protein 2 (MRP2) inhibitors. quinoline 45-54 ATP binding cassette subfamily C member 2 Homo sapiens 80-110 34468737-0 2022 Mechanistic investigation of synergistic interaction of tocopherol succinate with a quinoline-based inhibitor of mammalian target of rapamycin. quinoline 84-93 mechanistic target of rapamycin kinase Homo sapiens 113-142 34288843-5 2022 The mTOR inhibitors bearing heterocyclic moieties such as quinazoline, thiophene, morpholine, imidazole, pyrazine, furan, quinoline are under investigation against various cancer cell lines (U87MG, PC-3, MCF-7, A549, MDA-231). quinoline 122-131 mechanistic target of rapamycin kinase Homo sapiens 4-8 34358095-8 2021 Molecular dynamic simulations with the parallel G4 formed by a 21-nt sequence present in k-RAS gene promoter, showed that the relative spatial orientation of the two methylated quinoline/isoquinoline rings determines the ligands mode and strength of binding to G4s. quinoline 177-186 KRAS proto-oncogene, GTPase Homo sapiens 89-94 34115933-0 2021 "Turn-On" Quinoline-Based Fluorescent Probe for Selective Imaging of Tau Aggregates in Alzheimer"s Disease: Rational Design, Synthesis, and Molecular Docking. quinoline 10-19 microtubule associated protein tau Homo sapiens 69-72 34115933-4 2021 Herein, four quinoline-based fluorescent probes (Q-tau) were judiciously designed using the donor-acceptor architecture for selective imaging of tau aggregates. quinoline 13-22 microtubule associated protein tau Homo sapiens 51-54 34115933-4 2021 Herein, four quinoline-based fluorescent probes (Q-tau) were judiciously designed using the donor-acceptor architecture for selective imaging of tau aggregates. quinoline 13-22 microtubule associated protein tau Homo sapiens 145-148 34199197-6 2021 Co-treatment with gap junction enhancers such as all-trans retinoic acid (ATRA) and quinoline showed potentiating effects with FSK on cell survival via activation of cAMP/PKA/CREB. quinoline 84-93 cAMP responsive element binding protein 1 Homo sapiens 175-179 34253149-0 2021 Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2. quinoline 64-73 protease inhibitors None 89-108 34178944-5 2021 Moreover, in silico molecular docking studies of the new quinoline derivatives with the target enzymes, human NAD (P)H dehydrogenase (quinone 1) and DNA gyrase, were achieved to endorse their binding affinities and to understand ligand-enzyme possible intermolecular interactions. quinoline 57-66 DNA topoisomerase II alpha Homo sapiens 110-159 34630959-0 2021 Synthesis and biological evaluation of novel quinoline analogs of ketoprofen as multidrug resistance protein 2 (MRP2) inhibitors. quinoline 45-54 ATP binding cassette subfamily C member 2 Homo sapiens 112-116 34630959-1 2021 Objectives: A new series of quinoline analogs of ketoprofen was designed and synthesized as multidrug resistance protein 2 (MRP2) inhibitors using ketoprofen as the lead compounds. quinoline 28-37 ATP binding cassette subfamily C member 2 Homo sapiens 92-122 34630959-1 2021 Objectives: A new series of quinoline analogs of ketoprofen was designed and synthesized as multidrug resistance protein 2 (MRP2) inhibitors using ketoprofen as the lead compounds. quinoline 28-37 ATP binding cassette subfamily C member 2 Homo sapiens 124-128 34630959-6 2021 Results: Compound 6d, a 4-carboxy quinoline possessing dimethoxy phenyl in position 2 of quinoline ring, showed the most MRP2 inhibition activity among all the quinolines and more than the reference drug ketoprofen. quinoline 89-98 ATP binding cassette subfamily C member 2 Homo sapiens 121-125 34630959-7 2021 MRP2 inhibition activity of compound 7d was less in comparison to that of compound 6d, indicating that carboxyl group in position 4 of quinoline may interact with MRP2. quinoline 135-144 ATP binding cassette subfamily C member 2 Homo sapiens 0-4 34630959-7 2021 MRP2 inhibition activity of compound 7d was less in comparison to that of compound 6d, indicating that carboxyl group in position 4 of quinoline may interact with MRP2. quinoline 135-144 ATP binding cassette subfamily C member 2 Homo sapiens 163-167 34630959-10 2021 The position of benzoyl in quinoline ring is important in inhibition of MRP2. quinoline 27-36 ATP binding cassette subfamily C member 2 Homo sapiens 72-76 34630959-11 2021 Generally, MRP2 inhibition activity of compound 7d was less in comparison to that of 6d, indicating that carboxyl group in position 4 of quinoline may interact with MRP2. quinoline 137-146 ATP binding cassette subfamily C member 2 Homo sapiens 11-15 34630959-11 2021 Generally, MRP2 inhibition activity of compound 7d was less in comparison to that of 6d, indicating that carboxyl group in position 4 of quinoline may interact with MRP2. quinoline 137-146 ATP binding cassette subfamily C member 2 Homo sapiens 165-169 35605838-0 2022 Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors. quinoline 29-38 carbonic anhydrase 9 Homo sapiens 90-111 35551038-0 2022 Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity. quinoline 28-37 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 63-68 35604288-0 2022 Computational targeting of allosteric site of MEK1 by quinoline-based molecules. quinoline 54-63 mitogen-activated protein kinase kinase 1 Homo sapiens 46-50 35604288-9 2022 We have reached the conclusion that these quinoline molecules could be checked by experimental studies to validate their use as allosteric inhibitors against MEK1. quinoline 42-51 mitogen-activated protein kinase kinase 1 Homo sapiens 158-162 35182885-3 2022 Our recent work demonstrated that certain quinoline-Schiff-base derivatives were good Nur77 mediators that exerted excellent anti-HCC activities in vitro and in vivo. quinoline 42-51 nuclear receptor subfamily 4 group A member 1 Homo sapiens 86-91 35426686-1 2022 Herein, we present a new annulation reaction of quinolinium salts with indoles and paraformaldehyde, which enables syn-diastereoselective construction of a vast range of fused tetrahydroquinolines via ruthenium-catalyzed hydride-transfer-initiated tandem functionalization of the quinoline skeleton. quinoline 280-289 synemin Homo sapiens 115-118 35586442-0 2022 Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer. quinoline 6-15 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 29-33 35098327-2 2022 Since the first clinical application of quinoline-based FAP ligands in 2018, FAP inhibitor (FAPI)-based PET imaging and radiotherapy have been investigated for a wide variety of diseases, both cancerous and non-cancerous. quinoline 40-49 fibroblast activation protein alpha Homo sapiens 56-59 35268797-3 2022 Our previous studies have found that the introduction of bicyclic aromatic rings, such as naphthalyl and quinoline groups, into the N"-methylene position of indoles" Nur77 modulators can effectively improve the anti-tumor activity of the target compounds. quinoline 105-114 nuclear receptor subfamily 4 group A member 1 Homo sapiens 166-171 35083851-8 2022 The use of Auto dock Vina (simina) to simulate molecular target docking shows that the development of quinoline and benzohydrazide groups is of great significance to MAOA inhibitors. quinoline 102-111 monoamine oxidase A Mus musculus 166-170 35149265-8 2022 Docking studies suggested that the endocyclic nitrogen of the quinoline ring, and exocyclic nitrogen of the sulfonamide functional group are coordinate with Zn(II) ion at active sites of NDM-1. quinoline 62-71 Beta-lactamase Escherichia coli 187-192 35092073-0 2022 Autophagic and apoptotic cell death induced by the quinoline derivative 2-(6-methoxynaphthalen-2-yl)quinolin-4-amine in pancreatic cancer cells is via ER stress and inhibition of Akt/mTOR signaling pathway. quinoline 51-60 AKT serine/threonine kinase 1 Homo sapiens 179-182 35092073-0 2022 Autophagic and apoptotic cell death induced by the quinoline derivative 2-(6-methoxynaphthalen-2-yl)quinolin-4-amine in pancreatic cancer cells is via ER stress and inhibition of Akt/mTOR signaling pathway. quinoline 51-60 mechanistic target of rapamycin kinase Homo sapiens 183-187 35198057-1 2022 In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them the hotspot of much productive research. quinoline 17-26 fibroblast activation protein alpha Homo sapiens 33-62 35198057-1 2022 In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them the hotspot of much productive research. quinoline 17-26 fibroblast activation protein alpha Homo sapiens 64-67